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Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies 
worldwide with a very high mortality. Because the success of the conventional 
therapies is limited, epigenetic therapy may represent an alternative for HCC 
management. ZBP-89 is known to induce Bak in HCC. However, it is unclear 
whether epigenetic mechanisms contribute to ZBP-89-mediated Bak.  
 
Histone acetylase 3 (HDAC3) is realized as a chemotherapy target and a 
biomarker of recurrence in HCC. HDAC3 is frequently overexpressed in HCC 
and its inhibition enhances the efficacy of anti-HCC chemotherapy. The pilot data 
have indicated that ZBP-89 reduced HDAC3 in HCC but the mechanism 
responsible was unknown. The post-translational modification of proteins 
functions as a key regulatory factor in cellular physiological procedures, such as 
ubiquitinoylation degradation. As a biomarker of HCC development and 
recurrence, it is important to understand how ZBP-89 mediates the reduction of 
HDAC3.  
 
This study focuses on if ZBP-89 regulates Bak expression through epigenetic 
mechanisms. It is designed to investigate whether DNA methyltransferases 
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(DNMTs), histone acetylases (HDACs) are involved in regulation of 
ZBP-89-induced Bak expression. The study also elucidates the mechanism how 
ZBP-89 reduces the level of HDAC3 protein. 
 
Methods and Results 
The levels of Bak and ZBP-89 as shown on western blots were reduced but 
DNMT1 and HDAC3 were increased in HCC cancer tissues compared to the 
corresponding non-cancer tissues. Co-immunoprecipitation experiments showed 
that ZBP-89 bound to HDAC3 and DNMT1 but not other epigenetic enzymes, 
such as HDAC4, DNMT3a and DNMT3b. To clarify if ZBP-89 affects the 
activities of HDACs and DNMTs, ZBP-89 was overexpressed in HCC cells. 
Enzyme activities of HDACs and DNMTs were determined using relevant assay 
kits. Results showed that overexpressed ZBP-89 inhibited the activities of HDACs 
and DNMTs. Further experiments indicated that ZBP-89-mediated Bak 
up-regulation might contribute to maintenance of histone H3 and H4 acetylation 
through inhibition of HDACs activity. In another set of experiments, we also 
found an increased Bak expression in HCC cells when the cells were treated with 
HDAC inhibitors (HDACi) VPA and TSA. HDAC3 siRNA also increased Bak 
expression.  
 
Both knockdown of DNMT1 expression and administration of DNMTs inhibitors 
(zebularine) induced Bak expression. Chromatin immunoprecipitation (ChIP) 
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showed that ZBP-89 bound to Bak promoter at the region from -3188bp to 
-3183bp and from -275 to -49. As ZBP-89 inhibits DNMT activity, it is essential 
to know whether its inhibition affectes DNA CpG methylation status and 
methyl-CpG binding protein (MeCP) binding. The results showed that ZBP-89 
overexpression inhibited MeCP2 binding to genomic DNA. The finding indicated 
that decreased MeCP2 binding to DNA might be due to decreased methyl-CpG 
number in Bak promoter, suggesting that ZBP-89 might affect CpG island 
methylation status. Therefore, the bisulfite modified DNA sequencing method was 
used to clarify if Bak promoter CpG island methylation status was altered after 
ZBP-89 overexpression. Results revealed that ZBP-89 overexpression could 
demethylate the CpG islands in Bak promoter.  
 
ZBP-89 overexpression dose-dependently reduced the expression of HDAC3 at 
protein level but not at mRNA level. Co-immunoprecipitation and western blot 
methods were used to analyze Peptidyl-prolyl cis/trans isomerase 1 (Pin1) and  
HDAC3, phospho-I kappa B (pIκB), and the result revealed that HDAC3 could 
bound with either Pin1 or pIκB to promote the reduced expression of HDAC3. 
 
Constructed mU6-siPin1 vector was used to knockdown Pin1 expression in HCC 
cells. We found that knockdown of Pin1 expression blocked ZBP-89-mediated 
HDAC3 reduction. Experiments performed in Pin1 allele-knockdown JB6 C141 
Pin1−/− and Pin1+/+ cells showed that the reduction of HDAC3 by ZBP-89 was 
greater in Pin1+/+ cells than in Pin1−/− cells, confirming the role of Pin1 in 
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ZBP-89-mediated HDAC3 reduction. Furthermore, the ZBP-89-mediated HDAC3 
reduction was suppressed by CAY10576, an IκB kinase (IKK) activation inhibitor 
but not by SN50, a p65/p50 translocation inhibitor, suggesting that HDAC 
reduction may depend on IκB kinase rather than NF-κB activity. .  
 
HCC xenograft mouse model was used to support the involvement of epigenetic 
mechanism in ZBP-89-induced Bak expression and its therapeutic effects against 
HCC. Results showed that ZBP-89 as well as HDAC inhibitor valproic acid (VPA) 
or/and DNMT inhibitor zebularine stimulated Bak expression and induced 
apoptosis of tumor cells in an HCC xenograft mouse model, arresting tumor 
growth. In HCC xenografe model, treatment by injection of Ad-ZBP-89 viral 
expression vector mediated ZBP-89 expression decreased HDAC3 expression, but 
not HDAC4.  
 
Conclusions 
In conclusion, the study demonstrates a novel mechanism through which ZBP-89 
mediates an epigenetic pathway to promote Bak expression, and induce apoptosis 
in HCC cells. It also reveals the mechanism of HDAC3 reduction by ZBP-89 is 
dependent on IκB, which requires the presence of Pin1. This pathway may help 
develop future epigenetic therapy against HCC.  
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本研究旨在研究 ZBP-89 调控 Bak 表达的表观遗传机制。同时，弄清楚 DNA
甲基化转移酶和组蛋白去乙酰化酶是否参与 ZBP-89 对 Bak 的调控作用，进一
步阐明 ZBP-89 对 HDAC3 降低通路的机制。 
 
方法和结果 
肝癌病人组织蛋白分析表明，相对于癌旁组织，肝癌组织 Bak 和 ZBP-89 蛋白
表达降低，而DNMT1和HDAC3表达升高。免疫共沉淀技术显示ZBP-89与HDAC3、 
DNMT1 结合，但不与 HDAC4， DNMT3a 和 DNMT3b 结合。相应地，HDAC3 和 DNMT1
免疫沉淀分析也显示三者形成免疫复合物。我们在肝癌细胞中过表达
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ZBP-89，验证它会不会影响 HDACs 和 DNMTs 的活性。实验结果表明过表达的
ZBP-89 抑制 HDACs 和 DNMTs 的活性。进一步发现 ZBP-89 调节的 Bak 表达可
能是通过抑制 HDACs 活性和维持组蛋白 H3 和 H4 乙酰化水平实现的。另一方
面，我们同样证明 HDAC 的抑制剂（HDACi）VPA 和 TSA 可以诱导肝癌细胞 Bak
表达，此外，siRNA 干扰 HDAC3 的表达同样可以诱导 Bak 表达。 
 
对 DNMT1 表达的抑制和使用 DNMT 抑制剂（DNMTi）Zebularine 也可以诱导 Bak
的表达。染色质免疫沉淀结果显示 ZBP-89 结合于 Bak 的启动子区域，从
-3188bp 到-3183bp，从-275 到-49。 ZBP-89 可以抑制 DNMT 的活性，那么
ZBP-89 是否会影响 DNA 中 CpG 岛甲基化状态和甲基化结合蛋白（MeCP2）的
结合能力，这一点仍需要进一步证实。结果表明 ZBP-89 可以抑制 MeCP2 结合
基因组 DNA。为进一步揭示 MeCP2 是否由于启动子区域 CpG 岛去甲基化影响
其结合能力，我们采用亚硫酸盐测序方法。测序结果显示 ZBP-89 过表达可以
影响 Bak 启动子 CpG 岛的甲基化状态，并促进其去甲基化。 
 
腺病毒介导的ZBP-89过表达降低HDAC3表达呈现剂量依赖性，然而HDAC3 的
mRNA 水平并没有受到 ZBP-89 的表达。免疫共沉淀方法和蛋白免疫印迹实验
用于分析 Pin1 和 HDAC3 复合物，磷酸化 IκB 和 HDAC3 复合物的结合情况。结




构建的 mU6-siPin1 表达质粒用于敲除肝癌细胞 Pin1 的表达，方法检测基因
表达水平。Pin1 的缺失表达阻碍 ZBP-89 介导的 HDAC3 降低。在 Pin1 敲除细
胞系 JB6 C141 Pin1−/− 和 Pin1 过表达细胞系的研究，ZBP-89 更加能促进
Pin1+/+细胞中 HDAC3 减少，而对 Pin1+/+的细胞则没那么明显。由此肯定了 Pin1
在 ZBP-89介导的HDAC3降低中的重要作用。进一步研究发现， IκB 激酶 (IKK)
抑制剂，CAY10576，能抑制 ZBP-89 介导的 HDAC3 的降低；而 SN50, p65/p50
人核抑制多肽，则不影响 HDAC3 的降低。研究结果证明 HDAC3 的降低依赖 IκB
通路，而不是 NF- κB 活性。 
 
我们用人肝癌细胞的裸鼠移植瘤模型研究ZBP-89调控Bak表达的表观遗传机
制，及其对肝癌的治疗效果。研究结果表明 ZBP-89 蛋白和组蛋白抑制剂 VPA
和 DNA 甲基化抑制 zebularine 都能抑制肿瘤的生长，并诱导肿瘤组织 Bak
表达及细胞凋亡。VPA和zebularine联合治疗的效果更好。研究也表明ZBP-89
可以在体内降低 HDAC3 蛋白水平。 
 
结论 
本研究揭示了 ZBP-89 调节 Bak 蛋白表达和肝癌细胞凋亡的表观遗传机制。同
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Chapter One: General Introduction 






Liver cancer in men is the fifth most frequently diagnosed cancer worldwide but 
the second most frequent cause of cancer death. In women, it is the seventh most 
commonly diagnosed cancer and the sixth leading cause of cancer death (Jemal et 
al., 2011). The highest liver cancer rates are found in East and South-East Asia 
and in Middle and Western Africa, whereas rates are low in South-Central and 
Western Asia, as well as Northern and Eastern Europe. Among primary liver 
cancers, hepatocellular carcinoma (HCC) represents the major histological 
subtype, accounting for 70% to 85% of the total liver cancer burden worldwide 
(Perz et al., 2006). HCC in parts of Asia and sub-Saharan Africa are largely 
associated with chronic hepatitis B virus (HBV) infection. HBV infection 
accounts for about 60% of the total liver cancer in these areas. 
 
It is well known that therapy resistance is a common clinical problem in HCC 
management, especially resistance to apoptosis is a principal mechanism through 
which HCC cells escape from various cell death inducers. Bak is a 
well-established initiator of the apoptotic signaling cascade (Chittenden et al., 
1995). The involvement of Bak in HCC development, progression and treatment 
has been documented. The level of Bak is reduced (Liu et al., 2003) or even 
non-detectable in HCC cells (Rousseau et al., 2007). The reduction of Bak 
contributes to the development and progression of HCC (Shigematsu et al., 
2011,Lee et al., 2011). The overexpression of Bak may sensitize HCC cells to 
apoptosis induced by the chemotherapeutic agent doxorubicin (Li et al., 2000). 
The significance of Bak in HCC cells is further supported by several experiments 
in which different agents induce apoptosis in HCC cells by stimulating Bak 
expression (Fernando et al., 2012,Caja et al., 2009,Wang et al., 2002,Hu et al., 
2001). Although the significance of Bak in HCC has been reported, the 
mechanism responsible for its regulation in HCC is largely unknown.  
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Apoptosis is a strictly programmed process that has been implicated in various 
physiological and pathological procedures. Biological hallmarks of apoptosis are 
descripted as chromatin condensation and nuclear fragmentation, which are 
accompanied by rounding up of the cell and reduction in cellular volume 
(pyknosis) and retraction of pseudopods (Kroemer et al., 2009). Disruption of the 
normal control of apoptosis has been linked with various pathological events, such 
as tumorgenesis and metastasis. Induction of cancer cell apoptosis has been 
applied in anti-cancer drug development. In HCC, anticancer drugs target tumor 
cells to apoptosis induction, which is the main function of therapeutics. Histone 
deacetylases inhibitors (HDACi) come into scientists’ focus, as HDACi are 
effective and potential in cancer chemotherapy. It has been realized by numerous 
studies that inhibition of histone deacetylases (HDAC) activity has tightly linked 
with apoptosis and cancer therapy. The comprehensive understanding of 
underlying mechanism of HDACs to induce apoptosis is important as HDACis’ 
effecticeness in cancer therapy.  
 
This chapter will summarize the recent studies on HDAC family and apoptosis 
regulation in HCC, and elucidate the potential therapeutics mechanism in which 
HDACs participate. 
 
1.2 The complexity of HDAC family and functions 
Two main families of enzymes maintain the equilibrium of protein lysine residues 
acetylation. Histone acetyltransferases (HATs) add acetyl groups to protein lysine 
residues, while HDACs remove that from proteins (Jenuwein et al., 
2001,Shahbazian et al., 2007). The cellular histone acetylation modification is 
tightly regulated by the reciprocal activities of HATs and HDACs. Acetylation 
initially is defined as histone modification in transcriptional regulation, but a 
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recent study reveals that it also targets other regulatory proteins, such as 
transcription factors and cytoskeletal proteins (Glozak et al., 2005). 
 
1.2.1 HDAC family 
Eighteen mammalian HDACs have been identified to date and are classified into 
four groups according to their homology to yeast deacetylases. class I HDACs are 
zinc-dependent enzymes showing homology to the yeast protein RPD3, including 
HDAC1, HDAC2, HDAC3, and HDAC8. They are ubiquitous and mainly located 
nuclear. HDAC1 and HDAC2 function as the catalytic subunits of large 
multiprotein complexes in sin3, Nurd and coREST, and HDAC3 in N-Cor/SMRT 
complex. These complexes bind to transcription factors and chromatin to regulate 
transcription (Di Marcotullio et al., 2011). Currently, Class I HDACs are 
considered to function and depend on association with multiprotein repressor 
complexes (Inche et al., 2006).  
 
Class II HDACs are also zinc-dependent enzymes sharing homology to the yeast 
protein HDA1, including HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and 
HDAC10. They are subdivided into two classes: class IIa HDACs (4, 5, 7 and 9) 
and class IIb HDACs (6 and 10) (de Ruijter et al., 2003). These HDACs are tissue 
specific and nuclear or cytoplasmic location. They can form complex with 14-3-2 
proteins, kinase and phosphatases for regulating their subcellular trafficking. They 
can also deacetylate non-histone proteins to regulate cytoskeletal dynamics, 
activate molecular chaperones-dependent nuclues receptor, and promote 
ubiquitin-dependent degradation. Class IV of HDAC has only HDAC11 in this 
group, showing similar characteristics with both class I and class II.  
 
class III HDACs are structurally distinct NAD-dependent sirtuins (SIRTs), 
containing SIRT1 to SIRT7. They are localized in the nucleus (SIRT1,6,7), 
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cytoplasm(SIRT2) or mitochondria (SIRT3,4,5). SIRTs not only deacetylate 
histones, but also substrates like FOXO, PGC1a, NF-kB, p53, to process cell 
survival, apoptosis, gene transcription, DNA repair, stress response, and genome 
stability. For example, SIRT1 directly deacetylates lysine-382 of p53, thereby 
regulating its function, and p53 in turn regulates cell turnover, apoptosis, and 
senescence (Ota et al., 2007). Furthermore, SIRT1 directly deacetylates the DNA 
repair factor Ku70, causing Ku70 blocking the pro-apoptotic factor Bax away 
from mitochondria, thereby inhibiting stress-induced apoptosis and cell death 
(Cohen et al., 2004).  
 
Many HDACs show ability to form multiprotein complexes with various proteins, 
targeting genomic DNA and gene expression through interaction with 
transcription factors, nuclear factors, DNA methyltransferases (DNMTs), and 
histone methyltransferase (HMTs). HDACs interact with transcription factors to 
regulate specific gene expression (Lee et al., 2012,Stronach et al., 2011). For 
example, HDAC-1/2/3 and HDAC-5/7 regulates transcription factors 
NF-E2-related factor-2 (Nrf2) and Krüppel-like factor-2 (KLF2) in many 
shear-responsive genes, and the cell cycle in ECs (Lee et al., 2012). Nuclear 
receptor-associated corepressor activity, including ER, RXR, PPARs, is affected 
by recruitment of HDACs. For example, HDAC7 can bind to ERalpha and repress 
ERalpha's transcriptional activity (Malik et al., 2010). Thyroid hormone 
receptor·retinoid X receptor (RXR) corepressor homo-complex phosphorylates 
HDAC and enhances HDAC activity in the corepressor (Jeyakumar et al., 2007). 
Epigenetic enzymes, such as DNMT3a/DNMT3b recruits HDAC1 to glut4 
promoter in adult intrauterine growth-restricted (IUGR) (Raychaudhuri et al., 
2008). HDAC1 forms complex with H3 (Lys-9) methyltransferase SUV39H1 and 
DNMT1 to activate estrogen receptor alpha (ER) gene expression (Zhou et al., 
2007), and HDAC2 regulates neuronal differentiation through direct interaction 
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with N-terminal of DNMT3b (Bai et al., 2006). 
 
1.2.2 Multifunction of HDACs 
Histone acetylation directly influences chromatin remodeling, and accessibility 
for basal transcriptional coactivators, whereas transcription factors acetylation 
regulate their transcriptional function to activate or suppress gene transcription 
(Yang et al., 2007). Although histones are primary substrates for HDACs, HDACs 
also deacetylate non-histone proteins such as p53, E2F1, RelA, YY1, TFIIE, 
BCL6 and TFIIF (Glozak et al., 2005). HDACs are epigenetic regulators that are 
important for the control of various pathophysiological events. Abnormal HDAC 
activity or expression has been observed in a variety of cancers, and meanwhile 
aberrant histone acetylation status has been found to be implicated in cancer 
development(Ropero et al., 2007,Sawan et al., 2010), suggesting that HDACs 
directly participate in functional apoptosis.  
 
1.3 HDACs and apoptosis 
A crucial role has also been demonstrated for histone acetylation in imposing 
replication timing of specific genomic regions, thereby, as it might lead to 
large-scale changes in gene expression. HDACs are overexpressed in several type 
of tumors and revealed to participate in the tumorigenesis and advance 
development via transcriptional repression of tumor suppressor genes (TSG), thus, 
inhibition of HDAC activity led to suppressed proliferation and enhanced 
apoptosis but not in normal cells (Nakagawa et al., 2007). In addition to altering 
pathways that promote angiogenesis, HDACs also modulate the balance between 
pro- and anti-apoptotic proteins (Cohen et al., 2004,Cohen et al., 2004).  
 
Furthermore, aberrant recruitment of HDACs to cis-regulatory elements of target 
genes cause gene misregulation by oncogenic DNA-binding fusion proteins, 
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which are normally found in leukemia. For example, RARα, which is a retinoic 
acid-activated transcription factor and considered to be a tumor suppressor gene, 
is fused to promyelocytic leukemia (PML) or PLZF genes in acute promyelocytic 
leukemia (APL). the oncogenic fusion proteins RARα/PML or RARα/PLZF 
recruit HDAC and associated co-repressor complexes, such as DNA- and histone- 
methyltransferases, leading to suppression of target gene transcription (Fazi et al., 
2005). Similarly, the AML1-ETO fusion protein works as a docking site for the 
N-Cor/Sin3/HDAC1 repressor complex and recruitment, thus function as a potent 




Table 1.1 Summary of the current knowledge of HDACs regulation of cancer 
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1.3.1 HDAC regulates apoptotic-related gene expression 
1.3.1.1 Class I and apoptosis 
The loss of the Rb tumor suppressor gene has been reported in many human 
tumors, and its mechanism in apoptosis is quite clearly understood (Sherr et al., 
2002). Rb recruits class I HDACs to repress gene transcription, induces apoptosis 
through suppression of HDACs’ protective role in tumor cells (Robertson et al., 
2000). It can be speculated that loss of class I HDAC activity could induce the 
expression of genes regulated by Rb. Furthermore, overexpressed HDAC1 causes 
reduced expression of p53 and von Hippel–Lindau protein, which in turn leads to 
the overexpression of HIF-1α, thus stimulating angiogenesis. However, HDAC 
inhibitors are able to reverse this process (Kerbel, 2008). A number of knockdown 
studies using small interfering RNA (siRNA) method have revealed that loss of 
HDAC1 leads to reduced proliferation, cell cycle arrest, and induction of 
apoptosis in human cancer cells (Glaser et al., 2003,Thangaraju et al., 2009). 
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HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with 
down regulation of E-cadherin, indicating that HDAC I family may cooperate to 
benefit cancer cell (Hayashi et al., 2010). siRNA-mediated silencing of HDAC1 
and HDAC3 in colon cancer cells induces apoptosis, increasing in the acetylation 
status of histone H4 (Thangaraju et al., 2009). HDAC1/2 knockout ceases cell 
proliferation mainly blocking at G1 phase, and undergoes apoptosis. Additionally, 
it is associated with up-regulation of the CDK inhibitors p21WAF1/CIP1 and p57Kip2 
expression (Yamaguchi et al., 2010). HDAC2 has been shown to suppress 
apoptosis in tumor cells and regulate chromatin compaction(Marchion et al., 
2009). HDAC2 is overexpressed in tumors which lacks  APC  (adenomatosis 
polyposis coli) tumor suppressor expression, and interacts with Wnt pathway to 
protect cancer cell form death. RNAi-mediated knockdown of HDAC2 in colonic 
cancer cells resulted in cell death, indicating a role for HDAC2 in protecting 
cancer cells against apoptosis (Zhu et al., 2004). Treatment with Class I HDAC 
inhibitors suppressed the proliferation of ovarian cancer cells in association with 
apoptosis (Hayashi et al., 2010). Knockdown of HDAC1 but not 2 in U2OS 
osteosarcoma cells has been shown to induce apoptosis (Senese et al., 2007), 
whereas HDAC2 knockdown, but not HDAC1 in HeLa cells, induce apoptosis 
through increases p21cip/WAF1 expression and dependent of p53 (Huang et al., 
2005). Studies showed that loss of HDAC1 increased apoptosis and significantly 
enhanced proliferation (Lagger et al., 2010), but other study revealed that HDAC1 
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deficiency induced apoptosis but also suppressed proliferation (Senese et al., 
2007). 
 
Study revealed that deletion of HDAC3 caused embryonic lethality, and its 
inactivation was associated with interruption in cell cycle progression, DNA 
damage and compromised repair and apoptosis (Bhaskara et al., 2008). Recently, 
silencing of HDAC3 has been found to induce the expression of p21CIP/WAF1 and 
cell cycle arrest in the G2/M phase in colon cancer cells (Wilson et al., 2006). 
p21WAF1 is epigenetically inactivated by histone hypoacetylation in the promoter, 
and treatment with HDAC inhibitors increase acetylation of the promoter and 
gene expression, leading to inhibition of tumor cell growth and apoptosis (Gui et 
al., 2004). Autotaxin is highly expressed in some cancer cells and contributes to 
their tumorigenesis, invasion, and metastases. HDAC3 and HDAC7 
collaboratively suppress ATX (Autotaxin) expression in cancer cells, suggesting 
that TSA-induced ATX expression is through inhibiting HDAC3 and HDAC7. 
Thereby, HDAC inhibitor TSA leads to apoptosis and Autotaxin expression 
through inhibition of HDAC3 and HDAC7 (Li et al., 2011). DBC1 (Deleted in 
bladder cancer protein 1) is a tumor suppressor showing ability to influence 
transcription regulation and apoptosis. In detail, DBC1 interacts and specifically 
inhibits the deacetylase activity of HDAC3, and alters its subcellular distribution 
to block the oncogenic effect of HDAC3. Knockdown of endogenous DBC1 in 
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cells and knockout in mouse tissues increased HDAC3 deacetylase activity (Chini 
et al., 2010). HDAC3 overexpression might be a poor prognostic indicator for 
recurrence of HCC post-liver transplantation (Wu et al., 2010).  
 
HDAC8 is considered to be a class I enzyme, although phylogenetic analysis has 
shown it to lie near the boundary of the class I and class II enzymes. HDAC8 is 
expressed in multiple tissue types and tumor cell lines. Inhibition of HDAC8 
expression and activity causes apoptosis in T-cell-derived tumor lines 
(Balasubramanian et al., 2008). It is possible that PLCγ1 is normally deacetylated 
by HDAC8, thus increased PLCγ1 acetylation activation activates apoptosis 
pathway by HDAC8 inhibition. It has been found that high level of HDAC8 
expression is associated with poor prognostic marker, poor overall and survival in 
Neuroblastoma, as knockdown of HDAC8 results in the inhibition of tumor cell 
proliferation (Oehme et al., 2009). Further analysis reveals that knockdown of 
HDAC8 does not cause apoptosis, whereas HDAC2 knockdown induces apoptosis 
in neuroblastoma cells. The above collective evidences indicate that HDACs 
suppress pro-apoptotic pathway activation and apoptosis. HDAC1, HDAC2 and 
HDAC3 proteins increase stepwise in benign, borderline and malignant tumors, 
indicating that HDAC I family may cooperate to benefit cancer cell. Suppression 
of Class I HDACs either by inhibitors or endogenous proteins contributes to 
cancer cell apoptosis and cancer therapeutic targets. 
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However, functions of Class I HDACs on cell apoptosis might be diverse even 
reversed. Recent study revealed loss of HDAC1 in embryonic stem cells, 
immortalized fibroblasts and F9 embryonal carcinoma cells leads to increased 
expression of HDAC2 protein, however, re-introduction of HDAC1 into HDAC1 
knockout ES cells reduces HDAC2 levels (Jurkin et al., 2011). Knockout of 
HDAC2 can also result in increased levels of HDAC1 (Yamaguchi et al., 
2010,Wilting et al., 2010). siRNAs against HDAC1 and HDAC3 reduces 
pro-inflammatory cytokine-induced beta cell apoptosis in INS-1 and primary rat 
islets, but the apoptotic effect is not observed when HDAC2 is knocked out 
(Lundh et al., 2012).  
 
1.3.1.2 Class II and apoptosis 
In the regulation of apoptotic procedure, caspase-3 cleaves HDAC4 and generates 
an amino-terminal fragment, which accumulates in the nucleus and acts as a 
transcriptional repressor to trigger apoptosis (Liu et al., 2004). Curcumin induces 
apoptosis in medulloblastoma cells, accompanied by reduced HDAC4 expression 
and its activity (Lee et al., 2011). These evidences suggest the suppressive ability 
of HDAC4 on apoptosis. Further study revealed that HDAC4 suppressed 
p21CIP/WAF1 expression through binding to the proximal region of the p21WAF1/Cip1 
promoter, deacetylating Histone H3 and initiating apoptosis (Roninson, 2002) in 
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ovarian carcinoma cells, cervical cancer cells, glioblastoma cells and breast cancer 
cells in a nonredundant fashion(Mottet et al., 2009). The pro-apoptotic activity of 
HDAC4 also can be testified independently from caspase maturation (Paroni et al., 
2007). Apoptotic signals, such as low-potassium or excitotoxic glutamate, 
promote nuclear accumulation of HDAC4, and its ablation by short interfering 
RNA treatment suppresses neuronal cell death in neuronal cells (Bolger et al., 
2005). 
 
HDAC5 expression is frequently reduced in cancer such as colon cancer and acute 
myeloid leukemia, and is associated with poor clinical outcome of lung cancer 
patients (Osada et al., 2004). HDAC5 is primarily localized to pericentromeric 
heterochromatin, and associated with heterochromatin assembly and maturation. 
Therefore, its depletion loosens heterochromatin and potentiates the effect of 
chemotherapeutic agents by facilitating access of drugs to DNA (Peixoto et al., 
2012). HDAC5 overexpression- induced spontaneous apoptosis is related to the 
expression of seven apoptosis-associated genes, including TNFR1 and Caspase-8. 
Thus tumor necrosis factor death receptor pathway appears to be associated with 
HDAC5-induced spontaneous apoptosis (Huang et al., 2002). Interestingly, 
HDAC5 depletion induced a DNA-damage response, which engages both the 
p53–p21WAF1/Cip1 and the p16INK4A–pRb pathways, and significantly decreased 
proliferation. These pathways can establish and maintain the growth arrest that is 
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typical of senescence and/or induce apoptosis (Peixoto et al., 2012). Through 
down-modulation of HDAC4 and HDAC5 and up-regulation of acetyl-histone-H3 
and -H4, miRNA-9* induce toxicity and lead to induction of apoptosis and 
autophagy in WM cells (Roccaro et al., 2010).  
 
HDAC6 is the sole HDAC to have two catalytic sites and an ubiquitin-binding site. 
It can bind directly to ubiquitinated proteins through an ubiquitin-binding domain 
(BUZ domain), and target cargo proteins for subsequent processing (Boyault et al., 
2006). DNA repair protein Ku70 stabilizes FLIP protein stability by inhibiting its 
polyubiquitination. FLIP inhibits apoptosis by blocking caspase 8 activation. If 
the Ku70–Bax complex is disrupted by Ku70 acetylation, Bax will translocate to 
mitochondria and induce apoptosis (Cohen et al., 2004). HDAC6 is a key 
regulator of Ku70 acetylation and FLIP protein stability (Subramanian et al., 
2011), thereby inhibition of HDAC6 by specific inhibitor Tubacin leads to 
Bax-dependent and caspase 8-dependant apoptosis induction (Kerr et al., 2012). 
These evidences suggest that the negtive effect of HDAC6 on cancer cell 
apoptosis. HDAC6 is required for the activation of heat-shock factor 1 (HSF1) 
and cyclindromatosis tumor suppressor gene (CYLD), thereby inhibition of 
HDAC6 results in apoptosis (Aldana-Masangkay et al., 2011). 
 
HDAC7 is a known repressor of the orphan nuclear receptor Nur77, inhibiting 
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T-cell receptor (TCR)-mediated apoptosis (Dequiedt et al., 2003). Overexpression 
of Nur77 is associated with apoptosis, whereas its absence inhibits TCR-mediated 
cell death. HDAC7 seems to be regulated by reversible phosphorylation, shuttling 
this deacetylase to the cytoplasm after TCR-dependent phosphorylation (Parra et 
al., 2007). Phosphorylation activation and subsequent nuclear exclusion by protein 
kinase D induce Nur77 expression and apoptosis in T cell hybridomas (Dequiedt 
et al., 2005). Autotoxin is highly expressed in some cancer cells and contributes to 
their tumorigenesis, invasion, and metastases. HDAC7 and HDAC3 
collaboratively suppress ATX expression in cancer cells, suggesting that TSA 
induce ATX expression and apoptosis by inhibiting HDAC3 and HDAC7 (Li et al., 
2011). 
 
1.3.1.3 Class III and apoptosis 
Recently, the sirtuins or class III HDACs have received much attentions. They 
play important roles in the regulation of gene expression, apoptosis, stress 
responses, DNA repair, cell cycle, genomic stability, et al, indicating that this 
group of HDAC is key regulator of normal cell growth and proliferation. SIRT1 
regulates histone acetylation levels (mainly K16-H4 and K9-H3 positions), and 
the deacetylation of transcription factors such as p53, p300 histone 
acetyltransferase, E2F1, the DNA repair ku70, NF-KB, and the androgen receptor 
(Wang et al., 2006,Bouras et al., 2005,Cohen et al., 2004). SIRT1 directly 
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deacetylates acetylated p53, impairs p53-mediated apoptosis and antagonizes p53 
transcriptional activity to regulate cell cycle progression (Lin et al., 2012). 
SIRT1-mediated inhibition of p53 transcriptional activity also affects the 
transcription of apoptosis-related target genes, including p21, BAX, PUMA, and 
NOXA (Motta et al., 2004,Langley et al., 2002). Overexpression of SIRT1 
contributes to cytokines IL-6 and IL-8 production and apoptosis resistance 
(Niederer et al., 2011). SIRT2 deacetylates Foxo3a, and increases RNA and 
protein levels of Bim, thereby SIRT2 enhances apoptosis. Furthermore, deletion 
of SIRT2 leads to the reduction of apoptosis due to an increase in acetylation of 
Foxo3a and a decrease in Bim levels (Liu et al., 2012).  
 
The role of SIRT3 in the mechanisms of cell death and cell survival is still 
controversial. SIRT3 plays a pro-apoptotic role in both BCL2-p53- and 
JNK-regulated apoptosis (Allison et al., 2007). Additionally, cells lacking SIRT3 
show decreased stress-induced apoptosis, indicating further support for a 
pro-apoptotic role of SIRT3 (Kim et al., 2010). However, SIRT3 maintains basal 
ATP levels and as regulator of mitochondrial electron transporter. In the cellular 
response to DNA damage when mitochondrial NAD+ levels fall below critical 
levels, SIRT3 and SIRT4 display anti-apoptotic activity, protecting cells from 
death (Yang et al., 2007). SIRT6 modulates apoptosis resistance and 
telomere-independent cellular senescence in human cells, and catalyzes histone 
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H3 lysine 9 deacetylation to control NF-κB dependent gene expression (Kawahara 
et al., 2009). Knockdown of SIRT7 in human cancer cell lines blocks cell 
proliferation and causes apoptosis (Vakhrusheva et al., 2008). As the tumor 
suppressor p53 is a substrate of SIRT7 and thus this sirtuin appears to interfere 
with p53 function, similar to SIRT1. whereas, cleavaged inactive 75kD SIRT1, 
75Sirtuin 1 blocks tumor necrosis factor α-mediated apoptosis in human 
osteoarthritic chondrocytes (Oppenheimer et al., 2012).  
 
1.3.2 HDACs regulate apoptosis through protein complexes  
HDAC1 and HDAC2 coexist within the same protein complexes. The highly 
homologous class I enzymes HDAC1 and HDAC2 are able to homo- and 
heterodimerise and are frequently recruited to the same repressor complexes 
indicating similar or partly overlapping functions (Hassig et al., 1998). HDAC1 
functions as a proapoptotic factor in TGF-β1-induced apoptosis. Overexpression 
of HDAC1 can enhance TGF-b1-induced apoptosis via inhibition of ERK1/2 
phosphorylation activation, and the rescue of HDAC1 expression in HDAC1 
RNAi cells can restore the apoptotic response of cells to TGF-β1. However, 
downregulation of HDAC2 by RNAi markedly enhances TGF-β1-induced 
apoptosis through activation of ERK1/2, suggesting that HDAC2 has a reciprocal 
role in controlling cell survival (Lei et al., 2010). Furthermore, The proliferation 
effect observed in HDAC1/HDAC2-deficient fibroblasts has been linked to 
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increased levels of the CDK inhibitors p21 and p57. These findings propose that 
the effect of HDAC1 on proliferation is cell type-specific. 
 
Active Cdk5, which is regulated by p25 and p29, regulates phosphorylation of the 
component(s) of the HDAC complex and its integrity, as well as the histone 
acetylation status during neuronal apoptosis (Fu et al., 2012). Furthermore, 
HDAC1 is a pathological substrate of Cdk5/p25 (Kim et al., 2008), the 
phosphorylation status of HDAC1 results in inhibition of its activity, therefore 
leads to enhanced transcription of cell cycle genes and abnormal cell cycle reentry. 
Through regulating the integrity of the HDAC complex or directly modulating the 
activity of HDAC, the interaction of Cdk5 with components of the HDAC 
complex and their Cdk5-dependent phosphorylation is important for HDAC 
functions and its regulated apoptosis. Active Cdk5 regulates phosphorylation of 
the component(s) of the mSds3/mSin3-associated HDAC1 complex and its 
integrity, as well as the histone acetylation status during neuronal apoptosis (Fu et 
al., 2012). It suggests that HDACs activity and its complex integrity participate 
brain-associated apoptosis and development. 
 
SDS3 protein is a key component of the HDAC-dependent Sin3A co-repressor 
complex, serving to maintain its HDAC activity. The constitutive expression of 
USP17 and its substrate SDS3 was involved in the inhibition of 
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anchorage-independent tumor growth and blocks cell proliferation, leading to 
apoptosis in cervical carcinoma cells (Ramakrishna et al., 2011). The authors 
further revealed that polyubiquitination of SDS3 increases its HDAC activity and 
apoptosis, as USP17-mediated apoptosis is reduced when the endogenous SDS3 
protein level is depleted. Mcl-1 ubiquitin ligase E3 (Mule) specifically targets 
HDAC2 for ubiquitination and degradation. Accumulation of HDAC2 in 
Mule-deficient cells leads to compromised p53 acetylation and cripple p53 
transcriptional activation, accumulation, and apoptotic response upon DNA 
damage (Zhang et al., 2011).  
 
In addition, HDAC3 can associate with the acetyltransferases p300 and 
p300/CBP-associated factor (PCAF) to reverse autoacetylation. Furthermore, the 
nuclear receptor corepressor SMRT (silencing mediator of retinoid acid and 
thyroid hormone receptor) stimulate the deacetylase activity of HDAC3 towards 
MEF2 and PCAF. The myocyte enhancer factor-2 (MEF2) family of transcription 
factors plays an important role in regulating cellular programs like muscle 
differentiation, neuronal survival, and T-cell apoptosis (Youn et al., 1999). 
Supporting the physical interaction and deacetylase activity, HDAC3 can repress 
MEF2-dependent transcription and inhibited myogenesis. HDAC5 nuclear 
translocation triggered by KN93 induced a marked loss of MEF2 activity and 
subsequent apoptosis (Linseman et al., 2003). HDAC5 is not a p53 target gene 
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and may act in a p53-independent manner, HDAC5 reduces cell growth rate and 
induces spontaneous apoptosis (Huang et al., 2002). HDAC7 localizes to the 
mitochondrial inner membrane space of several human cell lines. Upon induction 
of the apoptotic cascade, HDAC7 is released from mitochondria and, along with 
nuclear HDAC7, is redistributed to the cytoplasm. These results highlight a 
previously unrecognized link between mitochondria, histone deacetylases, and the 
initiation of apoptosis (Bakin et al., 2004).   
 
1.3.3 HDACs mediates non-histone deacetylation and apoptosis 
The role of HDACs in cancer is not restricted to histone deacetylation, but also to 
non-histone proteins deacetylation. Non-histone protein acetylation levels are also 
the result of a dynamic equilibrium between HATs and the HDACs.  
 
The acetylation of p53 is positively correlated with its nuclear stability and 
accumulation, since acetylated p53 prevents its ubiquitination and subsequent 
degradation. Methotrexate inhibits HDAC activity and lead to p53 acetylation 
(Yang et al., 2010). Thereby, Huang and his colleagues further revealed that 
methotrexate downregulated HDAC/EZH2 and induced apoptosis through 
stabilizing p53 acetylation and phosphorylation (Huang et al., 2011). p53 is 
acetylated at lysine residues by the acetyltransferase p300 and CBP, leading to 
destabilization of p53-MDM2 interaction and increase p53-mediated stress 
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response (Gu et al., 1997). Acetylated p53 is sufficient for blocking 
MDM2-mediated apoptosis (Tang et al., 2008,Thompson et al., 2004). 
Additionally, HDAC1 recruits MDM2 and removes acetyl groups from p53 to 
promote its degradation, leading to p53 transcriptional activity inhibition (Ito et al., 
2002,Juan et al., 2000). Thereby reduction of p53 level suppresses pro-apoptotic 
pathway function. For example, Overexpression of HDAC1 significantly inhibited 
p53 transcriptional activity and inducible apoptosis, inhibition of HDAC activity 
by TSA promotes p53-p300 interaction and recruitment of acetylated p53 and 
consequently inducing apoptosis (Li et al., 2012).  
 
SIRT1 interacts with transcription factor E2F1, and decreases its transcriptional 
activity, thereby enhances cellular apoptotic functions (Wang et al., 2006). p53 
has several acetylation sites, and its hyperacetylation stabilizes and activates it to 
trigger apoptosis and cell-cycle arrest (Brooks et al., 2003). SIRT1 directly 
deacetylates acetylated p53, thus the inhibition of SIRT1 facilitates DBC1 
pro-apoptotic function through p53-mediated pathway (Zhao et al., 2008). 
Furthermore, SIRT1 forms a complex with FOXO3a, and induces cell-cycle arrest 
and resistance to oxidative stress, but inhibits the ability of FOXO3a to induce 
apoptosis (Frescas et al., 2005). It is also reported that Smad7 is a new target 
molecule for SIRT1, and SIRT1 attenuates TGFβ-induced cell apoptosis through 
acceleration of Smad7 degradation, as Smad7 is required for TGFβ-induced 
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apoptosis (Okado et al., 2002).  
 
DBC1 was originally identified as a gene homozygously deleted in human 
chromosome 8p21 in breast cancer, thereby named deleted in breast cancer 1 
(Hamaguchi et al., 2002). After apoptotic stimuli, DBC1 undergoes a 
caspase-dependent processing, generating C-terminal p120 and p66 fragments that 
relocalize from the nucleus to mitochondria and sensitize the cells to apoptosis 
(Sundararajan et al., 2005). DBC1 is a specific inhibitor of SIRT1 deacethylase 
activity and that downregulation of DBC1 renders cells resistant to cellular stress 
(Kim et al., 2008). By inducing p53 and transcription factor FOXO deacetylation, 
SIRT1 inhibits apoptosis and promotes cell survival. Since SIRT1 is anti-apoptotic 
and overexpressed in cancer, the primary function of DBC1 is seemed to 
counteract SIRT1 activity in tumor cells (Huffman et al., 2007). Given the 
involvement of DBC1 in tumorigenesis and as a native inhibitor of SIRT1 
deacethylase, it opens up attractive ways to develop compounds able to modulate 
DBC1 and SIRT1 for clinical application. SIRT6 overexpression is selectively 
toxic to multiple types of cancer cells, mediated by the mono-ADP 
ribosyltransferase activity of SIRT6 and the subsequent activation of the p53 and 




1.3.4 HDACs degradation deficiency and apoptosis 
HDAC1 has been identified as a new target of Chfr (Checkpoint with FHA and 
RING domains) which is an E3 ligase ubiquitously and expressed in normal 
tissues, ubiquitinates target proteins involved in tumorigenesis (Yu et al., 2005). 
As a consequence of the Chfr action, HDAC1 is ubiquitinated and subsequently 
degraded, both in vitro and in vivo (Oh et al., 2009), leading to the depression of 
HDAC1-mediated inhibition of CDK inhibitor p21 (Vidal et al., 2000), and 
induction of G1 cell cycle arrest. These observations suggest that, HDACs 
degradation deficiency may also involved in cancer cell apoptosis. In addition, the 
degradation of HDAC1 uncovers a novel role of Chfr in tumor suppression. 
 
RENKCTD11 was identified as a putative tumor suppressor gene whose expression 
is enhanced by Retinoic acid, Epidermal growth factor and Nerve growth factor 
(Gallo et al., 2002). In particular, RENKCTD11 induces ubiquitination and 
degradation of HDAC1, that in turn deacetylases lysine518 of Gli1, enhancing its 
transcriptional activity (Canettieri et al., 2010). Notably, its expression is mutually 
exclusive to that of RENKCTD11 in developing GCPs in vivo. Ectopic expression of 
RENKCTD11 in medulloblastoma cells reduced HDAC1 levels, leading to inhibition 
of Gli1 activity and growth arrest (Canettieri et al., 2010). These findings 
highlight that the association of RENKCTD11 genetic loss and HDAC–Gli 
synergism in brain tumors, indicating the role of RENKCTD11 in HDAC1 
 25
degradation regulation in cancer cell growth. 
 
1.4 DNMTs and epigenetic modification 
1.4.1 DNMT family 
DNMTs, including DNMT1, DNMT3a and DNMT3b in mammals, catalyzes the 
transfer of a methyl group to DNA cytosine residues. DNMT1 is the most 
abundant DNA methyltransferase in mammalian cells, and is considered to be the 
key maintenance methyltransferase. It predominantly methylates hemimethylated 
CpG di-nucleotides in the mammalian genome. However, DNMT1 is also 
responsible for both de novo and maintenance methylation of tumor suppressor 
genes in human tumor cells (Ting et al., 2006). DNMT1 has several isoforms, 
including the somatic DNMT1, a splice variant (DNMT1b) and an oocyte-specific 
isoform (DNMT1o) (Jurkowska et al., 2011). DNMT1o is synthesized and stored 
in the cytoplasm of the oocyte and translocated to the cell nucleus during early 
embryonic development, while the somatic DNMT1 is always found in the 
nucleus of somatic tissue. DNMT3, including DNMT3a, 3b, and 3L, is a family of 
DNA methyltransferases that could methylate hemimethylated and unmethylated 
CpG at the same rate (Chedin, 2011). The architecture of DNMT3 enzymes is 




1.4.2 CpG islands methylation and HCC  
Generally, it is reported 50% of CpG islands in human genes is hypomethylated in 
the healthy organism. Gene promoter CpG islands methylation is now realized as 
the early basis in the development of HCC (Shen et al., 2012,Sceusi et al., 2011). 
Changes in DNA methylation patterns, including promoter hypermethylation and 
global hypomethylation, are thought to be early events in hepatocarcinogenesis. It 
clearly indicates further research into the promising area of HCC epigenetics.  
 
Gene promoter methylation and the subsequent loss of protein expression have 
been demonstrated to involve the tumour suppressor. The study of methylation in 
HCC is also challenging as there are several well-known risk factors for HCC, 
such as alcohol-induced cirrhosis and chronic viral hepatitis B or C infection. 
Recently, studies have begun to investigate the global CpG promoter methylation 
in HCC patient samples. A total of 56 CpG sites, corresponding to 49 genes, were 
differentially methylated, including the APC gene located on chromosome 5 
(Archer et al., 2010). The study also demonstrated significant promoter 
hypermethylation in genes. APC protein expression was significantly reduced in 
HCC samples compared with samples of the adjacent non-tumour tissue (Csepregi 
et al., 2008). These silent genes were observed in tumor suppressor genes 
deficient expression, such as p15, p16, E-cadherin or SOCS-1 in HCC (Nishida et 
al., 2008,Matsuda et al., 1999).  
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p15INK4b/CTNNAB, a well established tumor suppressor gene (Kool et al., 
2010), encodes an inhibitor of cyclin-dependent kinases, and illustrates many of 
the principle of epigenetic correlative science and biomarker discovery.  
Methylation status of p15 was revealed as indicator in poor prognosis (Zhang et 
al., 2009,Wemmert et al., 2009). Results showed that patients with p15 promoter 
methylation reduced the overall survival time by 13 months, and another study 
suggested a positive prognostic significance of p15 in AML in a cohort of 107 
AML patients (Deneberg et al., 2010). Aberrant methylation and impaired 
expression of p15 has been shown to be is frequent in the human HCC. The 
identification of bivalent chromatin and EZH2 recruitment to the p15 promoter, as 
well as RNA directed epigenetic silencing, suggests that p15 will continue to be 
an ideal model for the investigation and development of biomarkers to be used in 
conjunction with new strategies to re-express epigenetically silenced genes (Geyer, 
2010).  
 
Regulation of DNMT1 and DNMT3A by HBx can promote hypermethylation of 
p16INK4A promoter region (Zhu et al., 2010). Methyl-CpG binding domain 
protein 2 (MBD2), an important methyl-DNA binding protein, was also studied in 
DNA methylation procedure together with DNMTs. It is a transcriptional 
repressor with an affinity for methylated DNA (Barr et al., 2007). A 
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tumor-suppressor role for p15 has been hypothesized based on gene inactivation 
associated with promoter hypermethylation in HCC.  
 
E-cadherin/CDH1 is a transmembrane glycoprotein that mediates 
calcium-dependent intercellular adhesion in normal epithelium. E-cadherin 
expression is frequently reduced or absent in a variety of epithelial cancers, and 
numerous studies have demonstrated a high frequency of 5’ CpG island CDH1 
methylation (Corn et al., 2000). Based on the frequency of its acquired epigenetic 
silencing in multiple different studies, CDH1 represents an excellent candidate 
methylation biomarker. An acquired autoactivating mutation V617F in the JAK2 
tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative 
neoplasms (MPN).  
 
1.5 Perspectives 
Histone deacetylases are the target of several structurally diverse compounds 
known as HDAC inhibitors (HDACis). Of note, these compounds were used as 
inhibitors long before a clear understanding of the role of specific HDACs in 
normal and/or transformed cells began to emerge. HDACs Inhibition can result in 
the induction of apoptosis through extrinsic and intrinsic pathways, cell cycle 
arrest, induction of differentiation, antiangiogenic, anti-invasive and 
immunomodulatory functions. These compounds can induce cytodifferentiation, 
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cell cycle arrest and apoptosis of transformed cells. HDACis are considered to be 
the most promosing anti-cancer drugs for cancer therapy, and many are being 
tested in phase I/II clinical trials. Many inhibitors show bright further in cancer 
therapy, and some have been approved by the Food and Drug Administration for 
the treatment of cancer. 
 
A more general and comprehensive consideration also needs to be addressed. Due 
to the facts that tumor cells are not homogeneous and cancer stem cells exist, it is 
reasonable to assure that the failure of current cancer therapy is in part due to the 
failure of cancer stem cell target. The actual roles of HDAC in cancer stem cell 
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ZBP-89, a Kruppel-type zinc-finger transcription factor, binds to gene promoter 
GC-rich sequence to activate or suppress gene transcription which is closely 
related to cell growth and cell death (Salmon et al., 2009,Wu et al., 2007). ZBP-89 
is thought to play important roles in tumor development and to be a potential 
target in cancer therapy. It can function as either an activator or a repressor, 
upregulating the expression of vimentin, epithelial neutrophil-activating 
peptide-78, β2-integrin CD11b, gastrin, ornithine decarboxylase, SOX18, p16, 
Pax7 and bovine adrenodoxin, downregulating p21/waf1, T cell receptors, 
lymphocyte-specific protein- tyrosine kinase, type 1 collagen , intestinal alkaline 
phosphatase, growth hormone receptor and stromelysin (Wu et al., 2007,Salmon 
et al., 2009,Feng et al., 2009,Merchant et al., 2003). Previously, our group 
reported that ZBP-89 induces Bak gene expression, a pro-apoptotic protein known 
to stimulate apoptosis in HCC cells (To et al., 2011). In addition to its ability to 
bind to gene promoters, ZBP-89 also forms protein-protein interactions (Woo et 
al., 2008,Wu et al., 2007). For example, ZBP-89 interacts with HDACs to repress 
p16 and vimentin gene transcription (Feng et al., 2009,Wu et al., 2007), or 
interacts with GATA-1 and/or FOG-1 to activate gene expression (Ohneda et al., 
2009,Woo et al., 2008). Although these studies proposed a link between ZBP-89 
and epigenetic regulation, the detailed mechanism is not understood. Therefore it 
is queried whether the regulation of Bak expression by ZBP-89 is subjected to 
epigenetic regulation. 
 
The interaction of HDACs and DNMTs plays an important role in gene silencing 
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(Gius et al., 2004,Cameron et al., 1999). Their role in the regulation of gene 
expression is tightly linked. HDAC and DNMT inhibitors can synergically 
regulate the same genomic targets (Gius et al., 2004). Alternatively, they may 
synergize when added together, although they activate different gene targets 
through different mechanisms (Cameron et al., 1999). Bak promoter methylation 
was reported previously (Pompeia et al., 2004,Ochs et al., 2000), however, the 
role of DNMTs on Bak methylation is unknown. It has been reported that an 
increase in the acetylated histone H3 and histone H4 is closely correlated with 
gene expression (Nandakumar et al., 2011). However, histone hyperacetylation is 
not always the result of a loss of HDAC enzyme activity, as it could also be due to 
a loss of HDAC recruitment to specific DNA sequences (Espada et al., 2004). 
Class 1(HDAC1, 2 ,3 and 8) and Class II (HDAC4, 5, 6, 7, 9 and 10) of HDACs 
play roles in HCC development and recurrence. Furthermore, HDAC3 is regarded 
as a biomarker of HCC recurrence and therapy target (Lachenmayer et al., 
2012,Wu et al., 2010). 
 
CpG dinucleotide islands are usually located in the promoter region of given 
genes. At these locations, the CG dinucleotide is not methylated. By contrast, CG 
dinucleotides that become methylated suppress gene expression. Therefore DNA 
methylation may silence gene expression through either interfering with 
transcription factors binding (Thain et al., 1996) or recruiting methylated DNA 
binding proteins (MBDs) (Nan et al., 1997). Several methylated DNA binding 
proteins including methyl-CpG-binding protein 2 (MeCP2), MBD1, MBD2 and 
MBD3 suppress gene expression via recruitment of other proteins such as SIN3A 
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and histone modifying enzymes (Ng et al., 1999). Aberrant genome-wide DNA 
methylation mediated by DNMTs has been thought to be related to tumorigenesis. 
Increased expression of DNMTs in HCC patients are correlated with poor 
prognosis and survival (Saito et al., 2003). 
 
Bak is a pro-apoptotic protein and its expression is suppressed in HCC. Our group 
previously reported that ZBP-89 induced Bak gene expression. However, ZBP-89 
does not directly bind to the Bak promoter. Therefore, the aim of this study was to 
determine whether ZBP-89 regulates Bak gene expression through its ability to 
modulate DNA methylation and histone acetylation levels and activity. 
Furthermore, whether the interaction affected the activity of HDACs and DNMTs 
was also studied. 
 
2.2Materials and Methods 
2.2.1 Hepatocellular carcinoma patient samples and cell lines 
One hundred and three HCC tissue samples and the matched non-cancer liver 
tissue samples were obtained from patients with HCC, who underwent surgical 
resection. Informed consent was obtained before the sample collection. The study 
was approved by the Joint Chinese University of Hong Kong – New Territories 
East Cluster Clinical Research Ethics Committee. Among these 103 patients, 28 
subjects carried the diagnosis of well-differentiated HCC, 43 subjects had 
moderately-differentiated HCC and 32 had poorly differentiated HCC. All tissue 
specimens were confirmed by histological examinations. Tissue samples were 
stored in a liquid nitrogen tank until analyzed. The human HCC cell line 
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PLC/PRF/5 and HepG2 were obtained from American Type Culture Collection 
(Rockville, MD). PLC/PRF/5 and MIHA (the immortalized non-tumorigenic 
human hepatocyte cell line) were maintained in Dulbecco’s modified Eagle 
medium (Invitrogen, Carlsbad, CA), and HepG2 was maintained in Minimum 
Essential Medium Eagle (Invitrogen, Carlsbad, CA), supplemented with 10% 
heat-inactivated fetal bovine serum at 37 °C with 5% CO2. 
 
2.2.2 Chemicals and reagents 
Antibodies against ZBP-89, PARP, Bak, Ac-Histone H3 (Lys9/12), Ac-Histone 
(Lys14), MeCP 2 and protein A/G PLUS-agarose beads were obtained from Santa 
Cruz Biotechnology (Santa Cruz Biotechnology Inc., CA). HDAC3, HDAC4, 
DNMT1 and DNMT3a, DNMT3b antibodies were provided by Cayman 
Chemicals (Ann Arbor, MI). ZBP-89 siRNA, HDAC3 siRNA and DNMT1 siRNA 
were purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology Inc., 
CA). VPA and Zebularine were purchased form Enzo Life Science (Thermo, IL). 
TSA, 5-aza-2’-deoxycytidine and DAPI were purchased from Sigma-Aldrich 
(Sigma-Aldrich Inc. St. Louis, MO). All other chemicals and reagents which were 
not mentioned were purchased from Sigma-Aldrich (Sigma-Aldrich Inc. St. Louis, 
MO) unless otherwise specified. 
 
2.2.3 Cell proliferation  
Cell proliferation was determined by MTT assay as described previously (Ye et al., 
2011). Briefly, approximately 1×104 cells were seeded in 96-well microculture 
plates and incubated overnight. In the second day, different treatments were 
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carried out and incubated for 0 to 4 days depended on the specific experiment. 
After incubation, chemical MTT 20 μl (5 mg/ml) was added to each well to the 
final concentration of 50 μg/ml, and the cells were further incubated for 4 h at 37 
oC. At the end of the incubation, remove supernatant carefully without disturb the 
cells in the bottom and added 200 μl DMSO into each well. Shake the whole plate 
for 15 min. The microtiter plate was spectrophotometrically read at a wavelength 
of 570 nm, with a reference wavelength of 630 in a multi-well plate reader 
(Bio-Rad, Hercules, CA). Cell proliferation rate (%)= (Absorbance of treated 
cell/Absorbance of untreated cell) ×100% 
 
2.2.4 Adenovirus infection of cells 
The replication-deficient recombinant adenoviral expression vector Ad-ZBP-89 
used in this study and was previously confirmed to express full length human 
ZBP-89(Bai et al., 2000). The experiment was performed according to the 
previous protocol (To et al., 2011). The stock of Ad-ZBP-89 adenovirus is 1×109 
pfu (Plaque forming units). The viral multiplicity of infection (MOI) was tested 
before infection. Briefly, by seeding 1×105 cells/well in 24-well plate, virus MOI 
of 1, 10, 50, 100, 200 were added to treated wells respectively. The infection 
effect was observed under microscopy, and testified through Western Blotting 
analysis of ZBP-89 expression and Bak expression. In the study, it was found that 
MOI of 100 showed great effectiveness induction of HCC cells apoptosis and 
pro-apoptotic protein Bak expression. The MOI of 100 was selected as 
Ad-ZBP-89 vector concentration to induce ZBP-89 expression. Cells infected 
with Ad5 vector alone were used as a control for each experiment. 
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2.2.5 Apoptosis detection 
The detection of apoptosis was using the Vybrant® Apoptosis Assay Kit #2 
(Invitrogen, Carlsbad, CA). According to the introduction of manufacture, the 
experiment was carried out with some modifications. The Alexa Fluor® 488 dye 
was conjugated to recombinant annexin V. Alexa Fluor® 488 dye is an almost 
perfect spectral match to fluorescein (FITC), but it creates brighter and more 
photostable conjugates. Propidium iodide (PI) nucleic acid binding dye is 
impermeant to live cells and apoptotic cells, but stains dead cells with red 
fluorescence, binding tightly to the nucleic acids in the cell. Harvest 1×106 
cells/ml trypsin digestion and wash in cold PBS for 2 times, finally, cells were 
resuspended in 250 μl of 1X annexin-binding buffer. Add 5 μl of Alexa Fluor® 
488 annexin V and 1 μl of the 100 μg/ml PI to each 250 μl of cell suspension. 
After incubation the cells at room temperature for 15 minutes, analyze the stained 
cells by flow cytometry (Becton Dickinson FACScan, NY), measuring the 
fluorescence emission of 10×104 cells at 530 nm (FL1) and >575 nm (FL2). 
 
2.2.6 Transfection of siRNA and plasmid 
The experiment was performed according to the previous publication (To et al., 
2011). Briefly, 3×105 cells/ml were seeded in 6-well plates 1 day prior to 
transfection. ZBP-89 siRNA, HDAC3 siRNA, or DNMT1 siRNA each at 
concentrations of 10 μM were transfected into the cells with Fugene reagent 
(Roche, Indianapolis, IN). Briefly, add the designed concentration of siRNA with 
Opti-MEM medium up to 96 μl in 500 μl tube, then mix 6 μl of Fugene reagent 
softly and completely. Incubate at room temperature for 15 min. Add the final 
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mixture to 6-well plate according to the experiment. About 2-3 days later, cells 
were lysed in RIPA buffer on ice with protease inhibitors.  
 
2.2.7 Co-immunoprecipitation (co-IP)  
The immuoprecipitation used Protein A/G PLUS-agarose beads. All procedures 
were carried out on ice or in 4oC cold room. Cell lysates were obtained by 
resuspending cell pellets in NP40 buffer, and the volume were dependent on the 
quantity of cells. Lysates were pre-cleared with incubation with protein A/G 
PLUS-agarose beads with slowly shaking for 4 h. Then lysate was incubated with 
primary antibody overnight in 4 oC. Immunocomplexes were precipitated with 
incubating with Protein A/G PLUS-agarose beads for additional 4 h in 4 oC. 
Release the immunocomplexes by boiling in 2×SDS sample buffer for 5 min, and 
centrifuge the sample in 5,000 rpm. The supernatant cantained antiboby and 
targeted antigen and was suitable for further Western blot analysis. 
 
2.2.8 Western blotting  
Cells were lysed in RIPA buffer or NP40 lysis buffer containing protease 
inhibitors (0.1 mg/ml PMSF, 10-fold diluted Aprotinin). Equal protein extracts  
which were less than 20 μl (no more than 50 μg) were loaded to 8~15% 
SDS-PAGE gel wells, and electrophoresed for 1.5 to 2 h according the specific 
situation. After electrophoresis, the seperated proteins in PAGE gel was 
transferred onto Hybond membranes (GE Healthcare, Arlington Heights, IL) by 
electroblotting at 100 V for ~ 2 h. The membranes were blocked in 5% nonfat 
milk and then were incubated with the designated primary antibodies for 2 h, 
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followed by incubation with a HRP-conjugated secondary antibody for another 
hour. After the membrane was washed with Tris-buffered saline containing 
Tween-20, the reaction was visualized by means of the ECL reagent kit (GE 
Healthcare). The membrane was exposed to films for a period ranging from 30 sec 
to 5 min. 
 
2.2.9 Immunohistochemistry and Immunofluorescence  
The immunohistochemical examination was carried out according to the previous 
publication (Ma et al., 2010). The tissue sections were incubated with a primary 
antibody overnight at 4℃, followed by incubation with a HRP-labeled IgG 
secondary antibody. The antigen-antibody complex was visualized by the 
diaminobenzidine (DAB) method. PBS was used as a negative control instead of 
the primary antibody. For immunofluorescent staining, the cells were seeded on 
the Millicell EZ SLIDE (Millipore, MA) and incubated overnight. After different 
treatments, the cells were fixed with 4% paraformaldehyde for 30 min, followed 
by washing in 0.1% Triton X-100 with shaking for 10 min and then blocking with 
2% BSA for 30 min. Primary antibody incubation was performed at 4 oC 
overnight, followed by incubating with FITC- or Rhodamine-labeled secondary 
antibody for 1h then DAPI staining for 5 min. Fluorescent cells were visualized 
using the Zeiss Axioplan 2 microscope (Zeiss, Germany). 
 
2.2.10 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed based on the protocol 
previously published with some modifications(Lee et al., 2006). Briefly, 1×107 
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cells were treated with of 1% formaldehyde (final concentration) for 10 min to 
crosslink protein and nucleic acid. Wash cells twice using ice cold PBS containing 
protease inhibitors (1mM phenylmethylsulfonyl fluoride (PMSF), 1microgram/ml 
aprotinin and 1microgram/ml pepstatin A). Add protease inhibitors to PBS just 
prior to use, as PMSF has a half-life of approximately 30 minutes in aqueous 
solutions. Cells were washed with PBS and resuspended in ChIP lysis buffer (1% 
SDS, 10mM EDTA, 50 mM Tris-HCl pH8.0). Chromatin was sheared by 
sonication to -500 bp then incubated with 1 μg of the designated antibody with 
incubation overnight in 4 oC. Antibody-chromatin complexes were pulled down 
with Protein A/G agarose. Each precipitated sample was divided into two part, one 
part of the precipitate was used for Western blot analysis, and the other part was 
used for PCR confirmation of the Bak promoter. The samples were boiled for up 
to 1 h to remove formaldehyde prior to subsequent western blotting (Orlando, 
2000). For Bak primer sequence PCR detection, samples were washed with Low 
salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl 
pH8.0, 150 mM NaCl) and High salt wash buffer (0.1% SDS, 1% Triton X-100, 2 
mM EDTA, 20 mM Tris-HCl pH8.0, 500 mM NaCl) and LiCl buffer (0.25 M 
LiCl, 1% NP-40, 1% SDC, 1 mM EDTA, 10 mM Tris-HCl pH8.0), and eluted 
with ddH2O. Formaldehyde crosslinks were reversed by incubating at a 65°C 
water bath for 4 h. Recover DNA by phenol/chloroform extraction and ethanol 
precipitation. Wash pellets with 70% ethanol and air dry. Antibodies used for ChIP 
were anti-ZBP-89 (Santa Cruz) and IgG alone was used as a control (normal 
rabbit IgG, Santa Cruz).  
Primers to detect precipitated sequence:  
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S1_F1: GGGAGGATGGGAGGTTGGGGG;  
S1_R1: AGCCCCTGCCCTCAGGGTTC;   
S2_F2:GAGGTGGGGGAGAAGATCAAAGACA,  
S2_R2:CGGCACCCGGCTCCAATCAG.  
PCR procedures: 94 oC 4 min, 25 cycles of 94 oC 15s, 58 oC 15s and 72 oC 90s, 
followed by 72 oC 7 min and 4 oC until for use. 
 
2.2.11 Sodium bisulfite modified sequencing of Bak promoter  
Sodium bisulfite modified sequencing was carried out using the 377DNA 
sequencer (ABI) and gene promoter primers were designed using MSPPrimer, 
which is available at http://www.mspprimer.org/cgi-mspprimer/design.cgi. Briefly, 
1 μg of genomic DNA was modified and clear up by EZ DNA modification-Gold 
kit, according to the manufacture (Zymo Research, Irvine, CA). Briefly, Add 130 
μl of the CT Conversion Reagent to 20 μl of DNA sample in a PCR tube. If the 
volume of the DNA is less than 20 μl, make up the difference with water. Mix the 
sample by flicking the tube then centrifuge the liquid to the bottom of the tube. 
Place the sample tube in a thermal cycler and perform the following steps: 98 oC 
for 10 min and 64 oC for 2.5 h. Clear and collect the sample by Zymo-Spin IC 
Column. Add 600 μl of M-Binding buffer to Zymo-Spin IC Column, load the 
sample into the column. Centrifuge at full speed for 30 s. Add 100 μl of M-Wash 
buffer to wash the sample, and add 200 μl of M-Desulphonation buffer to the 
column and let stand at room temperature for 20 min. After incubation, centrifuge 
for 30 s at full speed. Finally, place the column into a new 1.5 ml microcentrifuge 
tube, and add 10 μl of M-Elution buffer directly to the column matrix. Centrifuge 
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for 30 s at full speed to elute the DNA. Aspirate 1-4 μl of eluted DNA for each 
PCR, using the following bak gene promoter primers:  
msp_F1: GTTTAGGTTGGAGTGTAGTGGGTTA,  
msp_R1: CCAAAATTATACCACTACACTCCTACC;  
msp_F2: GTGGTTATAGAGTAATTTTTTTTAGAGGGA,  
msp_R2: ACCTACCCAAAAAAACCTTAAACTT;  
After PCR products were purified, the PCR products were sequenced on an ABI 
sequencer. PCR procedures: 94 oC 4 min, 35 cycles of 94 oC 15s, 68 oC 15s and 
72 oC 90s, followed by 72 oC 7 min and 4 oC until for use. 
 
2.2.12 Histone deacetylase activity assay 
The effect of ZBP-89 on HDACs activity in cancer cells was assessed by the 
Fluor de Lys-Green HDAC Assay Kit (Enzo Life Science, Farmingdale, NY). The 
Fluor de Lys-Green HDAC Assay is a complete kit for measuring histone 
deacetylase activity in cell or nuclear extracts, immuoprecipitates or purified 
enzymes. It comes in a convenient 96-well format, with all reagents necessary for 
fluorescent HDAC or sirtuin activity measurements and calibration of the assay. 
The Fluor de Lys-Green HDAC Assay is based on the Fluor de Lys-Green 
substrate and Fluor de Lys-Green developer combination. The kit is a highly 
sensitive and convenient alternative method to radiolabeled, acetylated histones or 
peptide/HPLC methods for the assay of histone deacetylase. The assay has two 
steps. First, the Fluor de Lys-Green substrate which comprise an acetylated lysine 
side chain, is incubated with a sample containing HDAC activity. Second, 
treatment with the developer produces a fluorophore. The experiment procedures 
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were performed according to the manufacturer’s protocol. Briefly, an equal 
volume of assay buffer, diluted Hela cells extract, Hela cells extract plus 
trichostatin A (TSA), or the sample were added to a 96-well plate to represent 
blank, positive control, negative control and tested samples respectively. The 
diluted substrate and the samples in the microtiter plate were left to quilibrate to 
assay temperature. HDAC reactions were initiated by adding diluted substrate to 
each well and mix thoroughly. HDAC reactions were then proceeded for desired 
length of time and then stop them by addition of Fluor de Lys-Green Developer. 
The plate was incubated at room temperature for 15 min. Samples were read in a 
microplate-reading fluorimeter capable of excitation at a wavelength in the range 
480 nm and detection of emitted light in the range 540 nm. 
 
2.2.13 DNA methyltransferases enzyme activity  
DNMTs were prepared according to a previous publication(Frauer et al., 2011). 
The S-adenosyl-L-methionine was used as the methyl group donor. The activity of 
DNMTs was detected by the methyltransferase activity kit (Enzo Life Science, 
Farmingdale, NY). The reaction is DNMTs enzyme mediated. The enzyme which 
mediates the covalent transfer of a methyl group form the donor 
S-adenosyl-L-methionine to an acceptor which is provided by the kit. Briefly, the 
volume of transferase assay buffer, positive control, cell nuclear extract were 
equally loaded into 96-well microtiter plates. Prepare the assay buffer by diluting 
15 ml of the supplied Transferase Assay buffer concentrate with 135 ml of 
deionized water. This solution can be stored at 4 oC for 3 months. The assay buffer 
is used to prepare dilution of Methyltransferase Reaction Mix, Transferase 
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Detection Solution, Enzymes and substrates. The reaction mixture and detection 
solution were then added to each well. The reaction was stopped by adding ice 
cold isopropyl alcohol. The plate was read on a fluorimeter with an excitation of 
380 nm and detection of wavelength of 520 nm. 
 
2.2.14 Xenograft animal model 
The xenograft tumor model was generated by injecting 2×106 PLC/PRF/5 cells 
into the left axilla of nude mice and left to grow for 3 weeks. Tumor-bearing mice 
were received relevant treatments. The control group received 0.9% saline by i.p. 
The Ad-ZBP-89 recombinant adenoviral vector (1×1010 pfu) was administrated by 
direct injection to tumor tissues. The first injection was done at the beginning and 
the second at 7 days later. VPA was injected through i.p. 50mg/kg/d for 7 days 
according to the publication (Ecke et al., 2009). According to the 
publication(Holleran et al., 2005), Zebularine was given to tumor bearing mice at 
100 mg/kg/d by i.p. injection in a solution of 0.9% saline 7 times over 14 days. 
After treatment, the tumors were excised intact then weighted. Tumor tissues were 
subjected to H&E staining, immunohistochemical and immunofluoresence to 
detect tumor subtype, Bak expression and TUNEL analysis (In situ cell death 
detection kit, Roche) respectively (Miao et al., 2006).  
 
2.2.15 Statistical analysis 
Analyses were performed using SPSS (SPSS Inc, Chicago, IL). Statistical analysis 
was performed by paired t-test, Mann-Whitney U test or one-way ANOVA. P 
values of less than 0.05 were considered statistically significant. Results were 
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2.3.1 ZBP-89 interacts with DNMT1 and HDAC3 
The prior study showed that ZBP-89 regulated Bak gene expression(To et al., 
2011). ZBP-89 can regulate the expression of some molecules via interacting with 
epigenetic enzymes to modify target gene promoters(Feng et al., 2009,Wu et al., 
2007). There are a number of epigenetic enzymes which are closely associated 
with hepato-carcinogenesis, including DNMT1, DNMT3a, DNMT3b, HDAC1 
and HDAC4(Fan et al., 2012,Lachenmayer et al., 2012,Wu et al., 2010,Huang et 
al., 2010,Mei et al., 2010,Fan et al., 2009,Datta et al., 2008,Oh et al., 2007). 
Therefore, I examined if ZBP-89-mediated induction of Bak requires an 
epigenetic mechanism. Co-immunoprecipitation studies showed that ZBP-89 
protein interacted with DNMT1 and HDAC3, forming a complex that could be 
detected by ZBP-89 antibody as well as DNMT1/HDAC3 antibody (Fig. 2.1A). 
Further experiments suggest that these three proteins might exist as a complex 
(Fig. 2.1B and 2.1C). The confocal images showed that ZBP-89 and DNMT1 
co-localized primarily in the nucleus of PLC/PRF/5 and MIHA cells (Fig. 2.1D 
and 2.1E). After treatment with the HDAC inhibitor TSA, ZBP-89 migrated from 
the nucleus to the cytoplasm. Some DNMT1 protein appeared to co-migrate with 
ZBP-89 to the cytoplasm, while some DNMT1 protein remained in the nucleus. 
The study also found that ZBP-89 did not bind to HDAC4, DNMT3a and 











Figure 2.1 ZBP-89 interacts with HDAC3 and DNMT1 to form a complex.  
ZBP-89 bound to HDAC3 and DNMT1 to form a complex in MIHA and 
PLC/PRF/5 cells (A). However, ZBP-89 did not bind to HDAC4, DNMT3a and 
DNMT3b (F). Furthermore, this complex could be precipitated by HDAC3 
antibody and DNMT1 antibody respectively (B, C). ZBP-89 and DNMT1 were 
detected in HDAC3 immunoprecipitated complex (B), and ZBP-89 and HDAC3 
were detected in DNMT1 immunoprecipitated complex (C). Original and merged 
confocal images showed that ZBP-89 and DNMT1 formed a complex that was 
primarily located in the nucleus (D and E). Interestingly, HDAC inhibitor, TSA, 
could induce ZBP-89 and DNMT1 to migrate from the nucleus to the cytoplasm.  
 
2.3.2 DNA methyltransferase-1 and histone deacetylase 3 are overexpressed 
in cancer tissues 
Having demonstrated the link between ZBP-89 and DNMT1/HDAC3, I would 
like to check whether the regulation of Bak gene expression by ZBP-89 correlates 
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with DNMT1/HDAC3 in HCC. I thus examined the expression of DNMT and 
HDAC3 proteins in HCC samples. Detail information of HCC patients are listed 
in table 2.1. HCC tumors are classified into three major subtypes (well, 
moderately and poorly differentiation) according to their histological 
morphology(Roncalli et al., 2010,Lee et al., 2004). In order to elucidate the 
relationship between Bak, ZBP-89, and two chromatin-modifying enzymes, 
western blot was performed on 103 liver cancer tissues and their non-caner liver 
tissues (Fig. 2.2A). The results indicated that the levels of Bak, DNMT1 and 
HDAC3 were significantly different between actual cancer tissues and paired 
non-cancer tissues (P<0.05, Fig. 2.2B, 2.2C and 2.2D). The expression of 
DNMT1 and HDAC3 proteins were much higher in the cancer tissues compared 
to non-cancer tissues, whereas Bak expression decreased with neoplastic 
transformation. The study further found that Bak expression positively correlated 
with ZBP-89 protein expression, but the correlation is weak.(Fig. 2.2E).  
Therefore, the western blot analysis suggested that ZBP-89 expression closely 
correlated with the differentiation status of the cancer. Furthermore, 
immunohistochemical staining confirmed that a lower level of ZBP-89 (Fig. 2.1F), 
















Figure 2.2 Bak expression is related to ZBP-89, DNMT1 and HDAC3 in HCC 
The expression of Bak, ZBP-89, DNMT1 and HDAC3 in different differentiated 
HCC samples was examined. The grayscale density of proteins bands was shown 
in a bar chart, according to different HCC differentiation subtypes. Bak, DNMT1 
and HDAC3 levels were significantly different between cancer tissues and their 
paired non-cancer tissues (B, C and D). Furthermore, the decreased expression of 
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Bak showed a similar trend with ZBP-89 level in cancer tissues, the regression 
correlation was significant, P<0.01 (E). Immunohistochemistry examination of 
ZBP-89 and DNMT1 was performed on the liver tissue samples from HCC 
patients. Immunohistochemistry results showed that poorly differentiated HCC 
expressed less ZBP-89 protein compared with other types (F). DNMT1 expression 
significantly increased in poorly differentiated cancer tissues compared with 




Table 2.1 Summary of recruited HCC patients and their laboratory experimental 








2.3.3 Inhibition of HDACs and DNMTs induces Bak expression and apoptosis 
Since the levels of DNMT1 and HDAC3 were elevated in HCC (Fig. 2.2), the 
study tested whether the inhibition of these two enzymes would affect the HCC 
cell proliferation and Bak expression. Therefore, HCC cells were treated with the 
HDAC inhibitors VPA and TSA, and DNMT inhibitors Zebularine and 5-aza-dC. 
The results showed that VPA and Zebularine inhibited the proliferation of 
PLC/PRF/5, HepG2 and MIHA cells in a time- and dose- dependent manner (Fig. 
2.3A, 2.3B and 2.3C). Similar results were also obtained when the cells were 
treated with TSA and 5-aza-dC. VPA and Zebularine in combination showed even 
greater suppression on cell proliferation than either agent alone (P<0.05). 
Furthermore, both VPA and Zebularine induced Bak expression, and activated 
PARP cleavage-mediated apoptosis in PLC/PRF/5 and HepG2 cells (Fig. 2.3D, 
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2.3F). Both agents also enhanced the acetylation of H4Lys12. These data 
suggested that Bak expression is regulated by HDAC3 and DNMT1 and is likely 
related to histone acetylation. In addition, ectopic expression of ZBP-89 using the 
Ad-ZBP-89 expression vector clearly induced expression of the pro-apoptotic 

















Figure 2.3 HDAC and DNMT inhibitors, and ZBP-89 induce Bak expression  
VPA and Zebularine inhibited the proliferation of PLC/PRF/5, HepG2 and MIHA 
cells. Combination of VPA and Zebularine significantly suppressed cells 
proliferation (A, B and C). Data were shown as Mean±SD. Both VPA acid and 
Zebularine induced Bak expression and PARP-cleaved mediated apoptosis. 
Treatment of VPA and Zebularine increased histone H4 acetylation (D). 
Ad5-ZBP-89-mediated ZBP-89 overexpression up-regulated Bak expression in 
dose-dependent manner after 24 h infection (E). *, Zebu+VPA vs VPA, P<0.05; 
△，Zebu+VPA vs Zebu, P<0.05; ＃, Zebu vs VPA, P<0.05, one-way ANOVA 
analysis. HCC cells were treated with 400 mM VPA, 400 μl Zebularine or 
combined both drugs. Results showed that the combined treatment significantly 
induced apoptosis (F). 
 
2.3.4 Adenovirus mediated ZBP-89 expression inhibits HDACs activity 
Both TSA and VPA significantly suppressed the activity of HDACs in both 
nuclear and cytosol extracts in vitro (P<0.001, Fig. 2.4A and 2.4B). Surprisingly, 
ZBP-89 overexpression also slightly inhibited HDAC activity (P<0.05). Further 
western blot analysis showed that ZBP-89 could maintain acetylation at histones 







Figure 2.4 ZBP-89 inhibits HDAC and increases histone acetylation level 
Histone deacetylases activity analysis showed that ZBP-89 overexpression 
inhibited HDACs activity in both nucleus and cytosol extracts (A and B). TSA 
(100 nM) as an accredited HDACs inhibitor significantly suppressed HDACs 
activity in vitro. Interestingly. Western blot analysis showed that ZBP-89 
increased histone H3 acetylation (Lys9/Lys14) and histone H4 acetylation (Lys12), 
and decreased HDAC3 protein level (C, Lanes 2 and 3). HDAC3 siRNA 
upregulated the level of Bak (C, Row 1) and increased histone H3 and H4 
acetylation in PLC/PRF/5 and MIHA cells (C, Rows 2 and 3).  
 
2.3.5 ZBP-89 suppresses DNMTs activity 
The overexpression of ZBP-89 significantly inhibited DNMT activity in nuclear 
extracts (P<0.001, Fig. 2.5A). The activity was also suppressed by DNMTs 
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inhibitor Zebularine. Decrease in DNMT1 expression by siRNA increased Bak 





Figure 2.5 ZBP-89 suppresses DNMT activity 
The overexpression of ZBP-89 significantly inhibited DNMT1 activity in nuclear 
extracts (A). The activity was also suppressed by DNMTs inhibitor Zebularine. 
Decrease in DNMT1 expression by siRNA increased Bak expression (B Lane 1). 
ZBP-89 siRNA decreased Bak expression in both cell lines. Data were shown as 
mean ± SD in triplicate experiments. * P<0.05, *** P<0.001. 
 
2.3.6 Overexpressed ZBP-89 demethylates methyl-CpG islands 
DNMT1 has been reported to bind DNA at CpG islands de novo 
methylation(Rhee et al., 2002). Thus, the finding suggests that ZBP-89 might 
interfere with the promoter CpG methylation status by affecting DNMT1 activity. 
Using chromatin immunoprecipitation (ChIP), I measured the precipitated MeCP2, 
a protein that binds to promoter regions. In the ChIP experiment, two ZBP-89 
DNA binding sites, GGGGGCAGGGG and GGGAGGTGGGG(Woo et al., 2011), 
were identified (Fig. 2.6A and 2.6B). One binding site was very close to exon 1 
and the other was 3 kbp away from the transcriptional starting site (Fig. 2.6C). 
Furthermore, the precipitated products without proteinase K treatment were 
analyzed by SDS-PAGE and western blotting, showing that ZBP-89 
overexpression inhibited MeCP2 binding to genomic DNA (Fig. 2.6D). This 
finding indicated that ZBP-89 overexpression might modulate Bak expression by 
decreasing MeCP2 binding to DNA. Using two computer programs 
(http://www.mspprimer.org/cgi-mspprimer/design.cgi and 
http://www.urogene.org/methprimer/index1.html), it was found two potential CpG 
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islands in human Bak promoter, which are shown schematically in Fig. 2.6E. 
Bisulfite modification sequencing was performed on these 2 CpG islands and 
showed that ZBP-89 overexpression could demethylate the Bak promoter CpG 
islands (Fig. 2.6F). In the first CpG island, ZBP-89 overexpression demethylated 








Figure 2.6 Overexpressed ZBP-89 demethylates methyl-CpG dinucleotide  
Schematic figure of Bak promoter and ZBP-89 binding sites (A). Chromatin 
immunoprecipitation experiment showed ZBP-89 binding to two regions. One is 
very close to exon 1 and the other is 3 kbp away form transcription start site (B). 
204 bp S1 sequence which is 3 kbp away from exon1, and 228 bp S2 which is 
near exon1, were precipitated by ZBP-89 antibody and amplified by primers (C). 
MeCP2 binds to chromatin in a methylation-dependent manner and is associated 
with a core repressor complex to silence gene transcription. Results showed that 
adenovirus- mediated ZBP-89 overexpression decreased MeCP2 protein binding 
to chromatin (D). CpG islands in Bak gene promoter were predicted by online 
software and 2 potential CpG islands in Bak promoter were found (E). When 
ZBP-89 was overexpressed, some methylated CpG regions became demethylation 
(F).  
 
2.3.7 Downregulation of HDAC3 and DNMT1 enhances Bak expression 
Although the activities of HDAC3 and DNMT1 are affected by ZBP-89, it is still 
unknown if they directly participate in Bak regulation. The study therefore used 
HDAC3 siRNA and DNMT1 siRNA to knockdown the levels of HDAC3 and 
DNMT1 respectively. It showed that the knockdown interfered with the 
expression of both HDAC3 and DNMT1 and such interference enhanced Bak 





2.3.8 Xenograft nude mouse model reveals that Ad-ZBP-89 adenovirus 
diminishes tumor volume and induces Bak expression and apoptosis 
Thirty nude mice were randomly divided into 5 groups, saline, Ad-ZBP-89, VPA, 
Zebularine, and VPA plus Zebularine. After the treatment for two weeks, the 
significant reduction of tumor volume and weight was observed in mice treated 
with Ad-ZBP-89, VPA and Zebularine respectively, compared with the saline 
control (Fig. 2.7A). The most obvious inhibition was achieved by a combination 
of VPA and Zebularine. Immunohistochemical staining of Bak expression showed 
that ZBP-89, VPA and Zebularine enhanced Bak expression and induced 












Figure 2.7 Ad-ZBP-89, HDACi and DNMTi inhibit xenograft tumor growth 
Xenograft mouse model was established by injection of 1×106 PLC/PRF/5 cells 
into left axilla of nude mice and left to grow for 3 weeks. The mice were given 
saline, Ad-ZBP-89, VPA, zebularine and VPA plus zebularine. After treatments, 
mice were sacrificed by cervical dislocation. Xenograft tumor tissues were 
weighed and analyzed. The tumor volume was reduced in mice receiving 
Ad-ZBP-89, VPA and Zebularine alone or in combination(A). These treatments 
could also induce proapoptotic protein Bak expression in vivo as examined by 
immunohistochemical staining (B). The apoptosis was analyzed by TUNEL assay 
(C). * P<0.05; ** P<0.01. All tests were analyzed using Mann-Whitney U test and 





Figure 2.8 Schematic diagram of the potential mechanism used by ZBP-89 to 
demethylate Bak promoter  
In HCC, CpG islands in the Bak promoter are hypermethylated. MeCP2 binds to 
methylated CpG sequence and histones are deacetylated. All these changes may 
contribute to the reduction of Bak in HCC. Application of ZBP-89 may 
demethylate CpG island through suppressing the activities of DNMTs and 
HDACs, dissociating MeCP2 binding to CpG sequence, and increasing histones 




Bak is a well-established initiator of the apoptotic signaling cascade (Chittenden 
et al., 1995). The involvement of Bak in HCC development, progression and 
treatment has been documented. The level of Bak is reduced (Liu et al., 2003) or 
even non-detectable in HCC cells (Rousseau et al., 2007). The reduction of Bak 
contributes to the development and progression of HCC (Shigematsu et al., 
2011,Lee et al., 2011). The significance of Bak in HCC cells is further supported 
by several experiments in which different agents induce apoptosis in HCC cells by 
stimulating Bak expression (Fernando et al., 2012,Caja et al., 2009,Wang et al., 
2002,Hu et al., 2001). The overexpression of Bak may sensitize HCC cells to 
apoptosis induced by the chemotherapeutic agent doxorubicin (Li et al., 2000). It 
is well known that therapy resistance is a common clinical problem in HCC 
management. Resistance to apoptosis is a principal mechanism through which 
HCC cells escape from various cell death inducers. Although the significance of 
Bak in HCC has been reported, the mechanism responsible for its regulation in 
HCC is largely unknown. The previous study has indicated that ZBP-89 may 
target a certain region of Bak promoter to induce its expression and subsequently 
apoptosis. In this study I further demonstrated that ZBP-89 stimulated Bak 
expression through an epigenetic mechanism in HCC.  
 
There are some reports on the relationship between ZBP-89 and HDACs or 
HDACi. For example, sodium butyrate (NaB) can promote ZBP-89-mediated 
p21waf1 activation in human colorectal cancer cells (Bai et al., 2007). ZBP-89 
may recruit HDAC1 to the vimentin promoter to repress the expression of 
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vimentin in human cervical cancer HeLa cells (Wu et al., 2007). Furthermore, 
ZBP-89 and HDAC3 may form a complex to help HDAC3 bind to the p16 
promoter, resulting in p16 downregulation in human lung cancer cells (Feng et al., 
2009). So far, there is no report on effect of ZBP-89 on the epigenetic regulation 
of Bak. In the present study, the involvement of ZBP-89 in the epigenetic 
regulation of Bak is shown in HCC. First, the co-immunoprecipitation 
experiments showed that ZBP-89 protein could forming a complex with DNMT1 
and HDAC3, and this finding was supported by the confocal examination showing 
that ZBP-89 and DNMT1 were co-localized primarily in the nucleus. Interestingly, 
ZBP-89 along with a portion of DNMT1 could migrate from the nucleus to the 
cytoplasm when HCC cells were treated with HDAC inhibitor TSA. Second, 
ZBP-89 overexpression could inhibit the activities of HDAC and DNMT.  It was 
noted that such an inhibitory effect of ZBP-89 on DNMT was even much greater 
than the classic DNMT inhibitor, Zebularine. However, the inhibition of HDAC 
by ZBP-89 was much weaker than the traditional HDAC inhibitors TSA and VPA. 
Third, ZBP-89 could maintain histone H3 lysine 9/14 residues and histone H4 
lysine 12 residue acetylation status. Fourth, ZBP-89 could significantly inhibit the 
activity of DNMTs that participate in DNA CpG islands de novo methylation. 
Fifth, ZBP-89 overexpression could inhibit MeCP2 binding to genomic DNA and 
partially demethylate Bak promoter CpG islands. These findings evidently 
indicate that ZBP-89 is able to target multiple points in the epigenetic pathway to 
upregulate the expression of Bak in HCC.  
 
Having conformed that the level of Bak is reduced in HCC, especially in the 
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poorly-differentiated HCC3, and that ZBP-89 is able to promote the expression of 
Bak in HCC cells, the study further demonstrated that the expression of Bak was 
controlled by epigenetic elements in HCC. First, the expression of Bak in liver 
tissues of HCC is negatively associated with two important epigenetic enzymes, 
DNMT1 and HDAC3, both of which levels are increased in the HCC tumor 
tissues. Second, the inhibition of either DNMT1 or HDAC3 induces Bak 
expression and the maximal inhibition is achieved when both enzymes are 
simultaneously suppressed.  These results clearly indicate that both DNMT1 and 
HDAC3 participate in the expression of Bak in HCC. Third, two CpG islands 
were located in the promoter of Bak gene as the result of analysis of human Bak 
gene promoter. Further analysis showed that the Bak gene is methylated on the 
dinucleotide CpG islands found. It is well known that CpG island 
hypermethylation may inhibit transcription by interfering with the recruitment and 
function of basal transcription factors or transcriptional coactivators (Deaton et al., 
2011). Moreover, the hypermethylation of CpG islands near the transcriptional 
regulatory region can promote the recruitment of the methyl-CpG binding domain 
family proteins including MeCP2 to facilitate a repressive chromatin environment, 
resulting in silencing genes (Deaton et al., 2011). MeCP2 can also interact with 
HDAC-containing complexes to contribute to the histone deacetylation-mediated 
transcriptional repression (Nan et al., 1998). These concepts are consistent with 
the finding that ZBP-89 inhibits MeCP2 from binding to chromatin, and 
permitting demethylation of the CpG islands within the Bak gene, and subsequent 
induction of Bak expression. Though the study do not have data to show how 
ZBP-89 inhibits MeCP2 binding to chromatin, it is possible that ZBP-89 may 
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complete with MeCP2 to bind to genomic DNA, and dissociates MeCP2 from 
DNA (Fig. 2.8). On the other hand, ZBP-89 may inhibit the formation of 
HDAC3-MeCP2 complex as the finding showed that ZBP-89 decreased HDAC3 
protein level. The interaction between ZBP-89 and MeCP2 to enhance Bak 
expression in HCC appears to be reminiscent of the two other findings. The 
interaction between MeCP2 and HDAC3 contributes to ILK gene suppression 
(Kim et al., 2007). Curcumin can dramatically inhibit MeCP2 binding to the 
Neurog 1 promoter, contributing to its ability to demethylate the CpG island of the 
Neurog 1 gene and restore its expression. 
 
Finally, in vivo experiment demonstrated that the administration of ZBP-89 
significantly inhibited the growth of xenograft HCC tumor and such a 
tumor-inhibitory effect was comparable to that of Zebularine, a DNMT inhibitor, 
and VPA, a HDAC inhibitor. Importantly, along with the reduction of the tumor 
size, there was an increase in Bak expression and occurrence of apoptosis.  
 
In conclusion, the study shows that the expression of Bak is reduced but the levels 
of DNMT1 and HDAC3 are increased in HCC cancer tissues compared with the 
corresponding non-cancer tissues. Correlation analysis reveals there is a negative 
association between Bak expression and DNMT1 level in HCC. The inhibition of 
either DNMT1 or HDAC3 induces Bak expression. ZBP-89 upregulates the 
expression of Bak via downregulating DNMT1 and HDAC3, maintaining histone 
acetylation status, inhibiting MeCP2 binding to genomic DNA and demethylating 
CpG islands in the Bak promoter. The application of ZBP-89 has shown a great 
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Chapter Three: ZBP-89 targets IkappaB to reduce HDAC3 via a 
Pin1-dependent pathway 
Chapter Three 






ZBP-89, a Kruppel-like zinc finger binding transcription factor, binds to gene 
promoter GC-rich sequence to activate or suppress gene transcription, which 
alters cell growth and cell death. Previously, our group has found that ZBP-89 can 
enhance the level of pro-apoptotic protein Bak but attenuate HDAC3 expression 
in HCC (Ye et al., 2012,To et al., 2011). HDAC3, a histone deacetylase enzyme, 
removes acetyl-residues from histones and forms transcriptional co-repressors 
with other proteins. HDAC3 can also act as a non-histone deacetylase 
(Lopez-Soto et al., 2009,Wu et al., 2011), playing an important role in physiologic 
and pathological conditions, such as apoptosis, tumorigenesis and metastasis. The 
high expression of HDAC3 has been documented in HCC (Lachenmayer et al., 
2012,Wang et al., 2012,Wu et al., 2010). The high level of HDAC3 is associated 
with the reduced recurrence-free survival in HCC. The inhibition of HDAC3 can 
lead to a strong anti-tumoral effect, which enhances the efficacy of 
chemotherapeutic agents in HCC (Lachenmayer et al., 2012,Wu et al., 2010). 
Furthermore, HDAC3 may contribute to the hapatocarcinogenesis by regulating 
microRNA-224 (Wu et al., 2010).  
 
Peptidyl-prolyl cis/trans isomerase 1 (Pin1), a highly conserved enzyme, 
specifically isomerizesphosphorylate Ser/Thr-Pro that bonds to certain proteins 
(Liou et al., 2011), which functions as a molecular switch to control the fates of 
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phospho-proteins. For example, Pin1 can regulate the phosphorylation or 
dephosphorylation of proteins to prevent or enhance protein degradation and it 
thus control diverse cellular processes including tumorigenesis. In HCC, Pin1 is 
able to form a complex with HBx and overexpressed in cancer tissues, indicating 
that it may promote hepatocarcinogenesis (Pang et al., 2007,Pang et al., 
2006,Chen et al., 2006,Pang et al., 2004). 
 
It has recently been shown that HDAC3 can be the substrate of Pin1 and 14-3-3 
protein (Rajendran et al., 2011). The 14-3-3 protects HDAC3 from degradation, 
whereas Pin1 promotes HDAC3 degradation. Therefore, the level of HDAC3 is 
regulated by competition between Pin1 and 14-3-3 proteins. In HCC, the pilot 
study has shown that ZBP-89 can inhibit HDAC3. Thus it appears that HDAC3 is 
subjected to the control by both ZBP-89 and Pin1. Interestingly, the functions of 
both ZBP-89 and Pin1 are closely associated with NF-κB, as Pin1 can stabilize the 
NF-κB subunit p65 to enhance its activity and ZBP-89 can compete with NF-κB 
to bind to the promoter of certain genes such as MMP-3 (Kuboki et al., 
2007,Jeong et al., 2009,Atkinson et al., 2009,Borghaei et al., 2009,Borghaei et al., 
2009). I therefore hypothesized that NF-κB played a role in the regulation of 
HDAC3 by ZBP-89 and Pin1 in HCC. The current study was to investigate the 
mechanism how ZBP-89 downregulated HDAC3 in HCC.  
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3.2 Materials and Methods 
3.2.1 Cell lines, chemicals and reagents 
The human HCC cell lines PLC/PRF/5 and HepG2 were obtained from American 
Type Culture Collection (Rockville, MD). The immortalized non-tumorigenic 
human hepatocyte cell line MIHA was a generous gift of Dr. Ming-Liang He. Pin1 
knockout cell line Pin1−/− and wild-type Pin1+/+ cell line were a generous gift from 
Dr. Zi-Gang Dong. PLC/PRF/5, MIHA, Pin1−/− and Pin1+/+ were maintained in 
Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA), and HepG2 was 
maintained in Minimum Essential Medium (Invitrogen, Carlsbad, CA). 
CAY10576, MG132, HDAC3 and HDAC4 antibodies were purchased from 
Cayman Chemical (Ann Arbor, MI). NF-κB inhibitory peptide SN50 was form 
Calbiochem (Darmstadt, Germany). Antibodies against ZBP-89, p65 and Pin1 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
Phospho-HDAC3 (Ser424) and phospho-IκBα (Ser32/36) antibodies was from 
Cell Signaling Technology (Beverly, MA). Ad-ZBP-89 viral vector was a 
generous gift from Dr. JL Merchant.  
 
3.2.2 Transfection of siRNA plasmid 
The experiment was performed according to the previous publication (To et al., 
2011). Briefly, 3×105 cells were seeded in 6-well plates 1 day prior to transfection. 
Pin1 siRNA sequence was constructed into mU6 siRNA vector which was a 
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generous gift from Dr. Guoliang Huang. mU6-siPin1 and mU6-siControl plasmid 
were transformed in JM109 bacteria and amplied. mU6-siPin1 or mU6-siControl 
plasmid was transfected into the specific cells with Fugene reagent (Roche, 
Indianapolis, IN). Briefly, add 2 μg of plasmid siRNA with Opti-MEM medium 
up to 96 μl in 500 μl tube, then mix 6 μl of Fugene reagent softly and completely. 
Incubate at room temperature for 15 min. Add the final mixture to 6-well plate 
according to the experiment. About 2-3 days later, cells were lysed in RIPA buffer 
on ice with protease inhibitors. Two days later, cells were lysed in RIPA buffer on 
ice with protease inhibitors. 
 
3.2.3 Plasmid extraction by mini-prep 
The plasmids were extracted following the protocol form QIAprep Miniprep 
(QIAGEN GmbH, Hilden, Germany). A single clony was picked from each 
freshly streaked LB ampicillin plate. It was then incubated for overnight at 37 oC 
with vigorous shaking at 250 rpm. The bacterial cells were collected by centrifuge 
at 6,000 rpm. The Palleted bacteria were then resuspended in 250 μl of Buffer P1 
with RNase A solution added and were transferred to a 1.5 ml microcentrifuge 
tube. 250 μl Buffer P2 was added to the tube and mixed thoroughly by inverting 
up-side down 4-6 times. 350 μl Buffer P3 was then added to the lysates and was 
mixed immediately by inverting the tube 4-6 times. After that, they were 
centrifuged for 10 min at 13,000 rpm. The supernatants were applied to the 
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QIAprep spin column by pipetting and were centrifuge for 1 min. The 
flow-through was discarded. Each of the QIAprep spin column was washed by 
adding 0.5 ml Buffer PB and was centrifuged for 1 min, followed by wash with 
0.75 ml of Buffer PE and centrifuge. The column was placed in a new 1.5 ml tube 
and the plasmid DNA was eluted with 30 μl of deionized water. The column were 
allowed to stand for 2 min and centrifuge at full speed for 2 min.  
 
3.2.4 Co-immunoprecipitation (co-IP) and Western blotting  
Co-IP experiment was carried out following the previous report(Zhang et al., 
2012). Briefly, lysates were incubated overnight at 4oC with the primary antibody 
after being precleared with protein A/G Plus-agarose beads for 4 h. Antibody was 
pre-incubated with Dynabeads Protein G beads (Invitrogen, Carlsbad, CA) in 
room temperature for 30 min. Cell lysates were incubated with antibody-beads in 
room temperature for 1 h, followed by magnet separation and PBS washes for 
three times. Immunocomplexes were released by boiling in 2×SDS sample buffer 
for Western blot analysis. 10% SDS-PAGE gels were used proteins were 
transferred onto Hybond membranes (GE Healthcare, Arlington Heights, IL) by 
electroblotting at 100 V for 2 h. After blocking with 5% nonfat milk, the 
membrane was incubated with the designated primary antibody for 2 h, followed 
by incubation with a HRP-conjugated secondary antibody for 1 h. The signal was 
visualized by ECL reagent. 
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3.2.5 Total RNA extraction 
Total RNA extraction use PureLink micro-to-mimi extraction kit (Invitrogen, CA). 
Follow the steps below to prepare lysates from 1×107–1×108 cells. Trypsinize 
cells and transfer detached cells to an appropriate tube. Centrifuge at 2,000 × g for 
5 minutes at 4°C to collect pellet. Remove the supernatant and add the volume of 
RNA Lysis Solution. Vortex at high speed until the cell pellet is completely 
dispersed and the cells appear lysed. Centrifuge the homogenate at ~2,600 g for 5 
minutes at room temperature. Transfer the supernatant to a clean 15-ml tube. 
Transfer up to 700 μl of the sample to the RNA Spin Cartridge pre-inserted in a 
collection tube. Centrifuge at 12,000 × g for 15 seconds at room temperature. 
Discard the flow-through, and re-insert the cartridge in the tube. Add 700 μl of 
Wash Buffer I to the spin cartridge. Centrifuge at 12,000 × g for 15 seconds at 
room temperature. Discard the flow-through and the collection tube. Place the 
spin cartridge into a clean RNA Wash Tube. Add 500 μl Wash Buffer II with 
ethanol to the spin cartridge. Centrifuge at 12,000 × g for 15 seconds at room 
temperature. Discard the flow-through, and re-insert the cartridge in the tube. 
Centrifuge the spin cartridge at 12,000 × g for 1 minute to dry the membrane with 
attached RNA. Discard the collection tube, and insert the cartridge into an RNA 
Recovery Tube. To elute the RNA, add 30–100 μl of RNase-free water to the 
center of the spin cartridge, and incubate at room temperature for 1 minute. 
Centrifuge the spin cartridge for 2 minutes at ≥12,000 g at room temperature to 
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elute the mRNA.  
 
3.2.6 Reverse transcription and real-time PCR 
Total mRNA was extracted by a commercial mRNA extraction kit (Invitrogen, 
Carlsbad, CA ). RT-PCR and real-time PCR was used the SYBR® Green™ 
Two-Step qRT-PCR Kit for ABI PRISM® (Invitrogen, Carlsbad, CA). The system 
contains two separate modules: (1) Use the SuperScript™ III First-Strand 
Synthesis SuperMix for qRT-PCR module for first-strand cDNA synthesis; (2) 
Use the SYBR® Green™ qPCR SuperMix for ABI PRISM® module for qPCR. 
Use the reagents provided in the SuperScript™ III First-Strand Synthesis 
SuperMix for qRT-PCR module to generate first-strand cDNA from up to 1 μg of 
purified total RNA. Combine the following kit components in a tube on ice. For 
multiple reactions, a master mix without RNA may be prepared: 10 μl of 2× RT 
Reaction Mix (includes oligo(dT)20 (2.5 μM), random hexamers (2.5 ng/μl), 10 
mM MgCl2, and dNTPs); 2 μl of RT Enzyme Mix (includes SuperScript™ III RT 
and RNaseOUT™); 1 μg total RNA; up to 20 μl of reaction system by adding 
DEPC-treated. Gently mix tube contents and incubate at 25°C for 10 minutes. 
Incubate tube at 50°C for 30 minutes. Terminate the reaction at 85°C at 5 minutes, 
and then chill on ice. Add 1 μl (2 U) of E. coli RNase H and incubate at 37°C for 
20 minutes. Use undiluted or diluted cDNA for following qPCR, or store the 
reaction at -20°C until use. 
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After the synthesis of first-strand cDNA, use the reagents provided in the SYBR® 
Green™ qPCR SuperMix for ABI PRISM® module to perform qPCR. The qPCR 
system contains: 25 μl of 1× SYBR® GreenER™ qPCR SuperMix for ABI 
PRISM®; 1 μl 200 nM forward primer and 1 μl 200 nM reverse primer, ≤5 μl 
cDNA template; by adding autoclaved distilled water up to 50 μl. Tightly Cap the 
reaction tube, and gently mix, gently centrifuge down all liquid to the bottom of 
the tube. Real-time PCR primers for HDAC3 were synthesized by Invitrogen. 
Forward primer: GCTGGAGGGAAAAGGAGTGG; Reverse primer: 
GGCCTTGGGAGAGAGAGGAA. Real-time PCR is carried out at 94oC for 30s, 
55oC for 30s and 72oC for 45s for 30 cycles, using ABI prism 7700 sequence 
detector machine and software to analyze the data (Applied Biosystems, CA). 
 
3.2.7 Immunohistochemistry and Immunofluorescence  
The tissue sections were blocked with SuperBlock buffer (Thermo, IL) for 30 min, 
then incubated with a primary antibody overnight at 4oC, followed by incubation 
with a HRP-labeled IgG secondary antibody with three washes in interval. The 
antigen-antibody complex was visualized by the diaminobenzidine method. 
Phosphate-buffered saline to replace the primary antibody was used as a negative 
control. For immunofluorescent staining, cells were seeded on the Millicell EZ 
SLIDE (Millipore, MA) and incubated overnight. After treatments, the cells were 
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fixed with 4% paraformaldehyde for 10 min, followed by washing in 0.1% Triton 
X-100 with shaking for 10 min and then blocking with 2% BSA for 30 min. 
Primary antibody was diluted with 2% BSA and incubated with cells at 4oC 
overnight, followed by incubating with FITC- or Rhodamine-labeled secondary 
antibody for 1h. Before covering the slide, Prolong Gold antifade reagent 
(Invitrogen, Carlsbad, CA) with DAPI stained the cells for 5 min. Fluorescent 
cells were visualized using the Zeiss Axioplan 2 microscope (Zeiss, Germany). 
 
3.2.8 Xenograft animal model 
The xenograft tumor model was generated by injecting 2×106 PLC/PRF/5 cells 
into the left axilla nude mice for three weeks. Tumor bearing mice were randomly 
divided into two groups, 10 mice per group. The therapeutic group was injected 
with ZBP-89 viral expression vector (1×1010 pfu) into tumor tissues, while the 
control group received saline injection. The first injection was done at the first 
days when tumor-bearing mice were divided into two groups, and the second 
injection was done at 7 days later. Two weeks after the 2nd injection, the tumors 
were excised intact and weighted. Tumor tissues were subjected to H&E staining 
and immunohistochemical staining. The tissue lysate was analyzed by Western 
blot to detect ZBP-89, HDAC3 and Bak expression. The use of mice for the 
experiment was approved by the CUHK animal research ethics committee.  
3.2.9 Statistical analysis 
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Analyses were performed using the Statistics Package for Social Sciences (SPSS 
for Windows, version 13.0, SPSS Inc, Chicago, IL). One-way ANOVA were used 
to compare means of three or more samples. t-test was used to compare the means 






3.3.1 ZBP-89 overexpression diminishes HDAC3 expression but not HDAC4 
The experiment found that ZBP-89 inhibited the expression of HDAC3 and 
pHDAC3 proteins but not HDAC4 (Fig. 3.1A), confirming the previous finding. 
In this study, I further examined if ZBP-89 could change subcellular distribution 
of HDAC3. After different dose- and time-exposures to ZBP-89, cytosol and 
nuclear extracts were respectively collected and subjected to Western blot. Results 
indicated that the decrease of HDAC3 and pHDAC3 protein mainly occurred in 
the nucleus (Fig. 3.1B). I further found that ZBP-89 did not change the level of 
HDAC3 mRNA as evident by RT-PCR analysis (Fig. 3.1C), suggesting that 








Figure 3.1. Reduction of HDAC3 by ZBP-89 
ZBP-89 overexpression attenuated HDAC3 expression but not HDAC4 in MIHA, 
PLC/PRF/5 and HepG2 cells. The level of HDAC3 was decreased in a 
dose-dependent manner by ZBP-89 (A). Cell lysate was obtained to separate the 
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cytoplasmic and nuclear fractions. The reduction of HDAC3 and pHDAC3 protein 
mainly occurred in the nucleus( B). RT-PCR analysis showed that the level of 
HDAC3 mRNA was not changed by ZBP-89 overexpression (C).  
 
3.3.2 Knockdown of Pin1 blocks ZBP-89-mediated HDAC3 reduction 
To study the role of Pin1 in the ZBP-89-mediated HDAC3 reduction, two 
approaches were used. First, the study examined the expression of HDAC3 in 
Pin1 knockout allele JB6 C141 Pin1−/− and Pin1 overexpression cell lines JB6 
C141 Pin1+/+ (Urusova et al., 2011), and found that the reduction of HDAC3 by 
ZBP-89 was much obvious in Pin1+/+ cells than in Pin1−/− cells (Fig. 3.2A and 
3.2B), suggesting the involvement of Pin1 in the ZBP-89-mediated HDAC3 
reduction. It also showed that Pin1−/− cells had higher level of HDAC3 and 
pHDAC3 than that in Pin1+/+ cells. Second, I used Pin1 siRNA to block the 
expression of Pin1 and then examined HDAC3 expression in MIHA and 
PLC/PFR/5 cells. Pin1 knockdown increased the levels of HDAC3 and pHDAC3 
(Fig. 3.2C). Further experiments showed that the block of Pin1 expression 
suppressed ZBP-89-mediated HDAC3 reduction in both cells (Fig. 3.2D). 
Accompanied the attenuation of ZBP-89-mediated HDAC3 reduction, 
ZBP-89-induced Bak was inhibited (Fig. 3.2D). Finally, using the co-PI method, 











Figure 3.2. Knockdown of Pin1 expression blocks ZBP-89-mediated HDAC3 
decrease.  
Pin1 allele-knockout JB6 C141 Pin1−/− and the overexpression JB6 C141 Pin1+/+ 
cells were infected with Ad-ZBP89 and the levels of HDAC and pHDAC were 
examined by western blot. It was found that Pin1−/− cells had higher level of 
HDAC3 and pHDAC3 than that in Pin1+/+ cells (*p<0.05, **p<0.01, #p<0.01, A 
and B). Cells were treated with Pin1 siRNA interfering plasmid which was 
constructed into mu6 vector to silence Pin1 expression. Results indicated that the 
inhibition of Pin1 expression increased the levels of HDAC3 and pHDAC3 in 
PLC/PRF/5 cells(C). MIHA and PLC/PRF/5 cells were pretreated with mu6-Pin1 
siRNA before Ad-ZBP-89 infection. Pin1 silence blocked ZBP-89-mediated 
reduction of HDAC3 (D). The up-regulated expression of Bak by ZBP-89 was 
also blocked by Pin1 siRNA(D). Co-IP result showed that Pin1 bound to HDAC3 
in PLC/PRF/5 cells (E).  
 
3.3.3 ZBP-89 reduces the level of IκB 
To examine the role of IκB, an endogenous inhibitor of NF-κB, in the 
ZBP-89-mediated HDAC3 reduction, Western blot was used to determine the 
level of IκB in cells treated with Ad-ZBP-89. It was found that ZBP-89 
overexpression stimulated IκB reduction (Fig. 3.3A). Accompanied with the 
reduction of IκB, the expression of HDAC3 was also decreased. The result was 
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confirmed in Pin1+/+ and Pin1−/− cells and it further demonstrated that 
ZBP-89-induced reduction of IκB was greater in Pin1+/+ cells than that in Pin1−/− 
cells (Fig. 3.3B). This finding indicates the involvement of Pin1 in 









Figure 3.3. ZBP-89 stimulated IκB phosphorylation to decrease HDAC3 Cells 
were infected with Ad-ZBP-89. Total proteins were isolated and subjected to 
western blot analysis of IκB and HDAC3. ZBP-89 reduced the level of IκB in a 
dose-dependent manner in HCC cells (A). The reduction of IκB was accompanied 
by HDAC3 decrease. IκB and HDAC3 reduction by ZBP-89 was much more 
obvious in Pin1+/+cells than that in Pin1−/− cells (B and C). Data shown as 
mean±SD. *p<0.01, **p<0.001, compared with their controls. #p<0.05.  
 
3.3.4 IκB degradation inhibitors suppresses ZBP-89-meditaed HDAC3 
reduction 
To explore how IκB was reduced by ZBP-89 and participated in the reduction of 
HDAC3, three different NF-κB inhibitors were employed to treat cells and the 
 106
level of pIκB was determined. It is known that IκB phosphorylation can lead to 
the degradation of IκB. CAY10576 is a selective inhibitor of IKK-ε whose 
activation can lead to the degradation of IκB and thus the activation of 
NF-κB(Bamborough et al., 2006). MG132, a proteasome inhibitor, can block the 
activation of NF-κB through preventing proteasome-mediated degradation of IκB 
(Ortiz-Lazareno et al., 2008). SN50 is a specific inhibitor of p50/p65 nuclear 
translocation and transcriptional activity but does not interfere with IκB 
degradation (Lin et al., 1995,Sun et al., 2012). Results showed that pretreatment 
with CAY10576 inhibited ZBP-89-mediated induction of pIκB in MIHA, 
PLC/PRF/5, Pin1+/+ and Pin1−/− cells (Fig. 3.4A and 3.4B). Similar results were 
obtained when the proteasome inhibitor MG132 was used. SN50 inhibited NF-κB 
translocation activity but did not affect the level of pIκB (Fig. 3.4C and 3.4D). 
Nevertheless, similar to SN50, both CAY10576 and MG132 could inhibit 
ZBP-89-mediated p65/50 translocation (Fig. 3.4F and 3.4G). However, 
importantly the ZBP-89-mediated HDAC3 reduction could be prevented by either 
CAY10576 or MG132 (Fig 4A and B), but not affected by SN50 (Fig 4C). 
Therefore, these data appear to suggest that the changes in IκB or pIκB rather than 
the activity of NF-κB are involved in ZBP-89-mediated HDAC3 reduction. Using 
co-IP and Western blot analysis, the study testified that both IκB and pIκB were 
able to bind to HDAC3 (Fig. 3.4E), suggesting a direct interaction between both 










Figure 3.4. ZBP-89 reduces HDAC3 via stimulating IκB phosphorylation 
  After cells were infected with Ad-ZBP-89, they were treated with CAY10576, 
MG132 and SN50. After the treatment, total protein was isolated and subjected to 
western blot analysis for pIκB and HDAC3. Either CAY10576 or MG132 
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inhibited pIκB as well as HDAC3 in MIHA, PLC/PRF/5 and Pin1+/+ and Pin1−/− 
cells (A and B). p65/p50 inhibitory peptide SN50 suppressed NF-κB translocation 
activity (D), but had no effect on pIκB (C). The level of ZBP-89 mediated 
HDAC3 reduction was also not affected by SN50 (C). Co-IP and western blot 
were employed to test if IκB and pIκB could bind to HDAC3. IκB and pIκB were 
both detected in the immunoprecipitated HDAC3 complex, indicating that 
HDAC3 can form a complex with IκB, as well as pIκB (E). 
 
3.3.5 ZBP-89 decreases HDAC3 but increases Bak in xenograft tumor tissues 
A nude mouse tumor model was established by subcutaneous injection of 
PLC/PRF/5 cells. The immunohistochemical staining of tumor tissues showed that 
positive staining of HDAC3 in Ad-ZBP-89 group was less than that in saline 
group. I randomly counted the positive-stained cells in 7 fields in every section, 
the statistical analysis revealed that the expression of HDAC3 was significantly 
decreased in mice treated with Ad-ZBP-89 compared with mice treated with 
saline (p<0.05, Fig. 3.5A and 3.5B). The immunohistochemical result was 
confirmed by Western blot analysis, as the level of HDAC3 protein was lower in 
mice treated with Ad-ZBP-89 than that of mice treated with saline (Fig. 3.5C and 
3.5D), but HDAC4 level did not show obvious difference (Fig. 3.5C). The data 
also confirmed that ZBP-89 could significantly increased the level of Bak (Fig. 










Figure 3.5 ZBP-89 decreases HDAC3 but increases Bak in xenograft tumor 
tissue 
Ad-ZBP-89 infection effectively enhanced ZBP-89 levels in 10 tumor-bearing 
mice. The expression of HDAC3 in xenograft tumor tissues was examined by both 
histochemical staining and western blotting analysis (A and C). Both methods 
showed that ZBP-89 overexpression significantly reduced HDAC3 expression 
compared with saline controls (*p<0.05, B and D), but the expression of HDAC4 
was not affected by ZBP-89 overexpression (C). ZBP-89 overexpression also 




In this study, I first confirmed the previous finding that ZBP-89 reduced both 
HADC3 and pHADC3 proteins in HCC cells. The level of HDAC3 is frequently 
increased in HCC (Lachenmayer et al., 2012,Wang et al., 2012,Wu et al., 2010), 
suggesting a possible role of HDAC3 in hepatocarcinogenesis. Indeed, the 
increased expression of HDAC3 is significantly correlated with DNA copy 
number gains in HCC (Lachenmayer et al., 2012), and HDAC3 acts on 
miR-224-residing locus in Xq28 to increase the level of miR-224, one of the most 
commonly up-regulated microRNAs in control of apoptosis and proliferation in 
HCC (Wu et al., 2010). The positive role of HDAC3 in the growth and 
progression of HCC is further supported by the inhibitory experiments, in which 
the downregulation of HADC3 results in a strong anti-tumoral effect and enhances 
the efficacy of chemotherapeutic agents in HCC (Lachenmayer et al., 2012,Wu et 
al., 2010). HADC3 may also serve as a biomarker for HCC recurrence as the high 
expression level of HDAC3 is associated with the reduced recurrence-free 
survival of HCC patients. Although HDAC3 is known to participate in the 
development, progression, treatment and survival of HCC, the molecular 
mechanism leading to its increase in HCC is unknown.  It is not surprising to 
find that ZBP-89 is able to reduce HDAC3 since there is evidence showing that 
the function of ZBP-89 is related to epigenetic events. For example, 
ZBP-89-induZBP-89 is known as an apoptotic inducer in HCC and studies have 
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demonstrated that ZBP-89 can enhance the pro-apoptotic molecule Bak (Ye et al., 
2012,To et al., 2011). The p21waf1 activation can be enhanced by HDAC inhibitor 
sodium butyrate (Bai et al., 2007). ZBP-89 and HDAC3 can form a complex to 
help HDAC3 bind to the p16 promoter, resulting in p16 downregulation in human 
lung cancer cells (Feng et al., 2009).  
 
It appears that there are some connections between HDAC3 and NF-κB or its 
subunits. NF-κB subunit p65 has been shown to recruit HDAC3 to the antioxidant 
response element of Nrf2 gene, leading to local histone hypoacetylation (Liu et al., 
2008). The activity of NF-κB is associated with the nuclear export of HDAC3, 
and HDAC3 efficiently inhibits CREB3-enhanced NF-κB activation (Winkler et 
al., 2012,Kim et al., 2010). The activation of NF-κB by cigarette smoke extracts 
via IKK phosphorylating on IκB is accompanied by reduction in HDAC 
levels/activity (Yang et al., 2006). IκBα is known to bind HDAC3 through its 
ANKYRIN amino acid repeats (Viatour et al., 2003). It is therefore wondered 
whether NF-κB or its subunits contribute to ZBP-89-induced the reduction of 
HDAC3 in HCC. To address this question, the study first demonstrated that 
accompanied with the reduction of HDAC3, ZBP-89 could enhance IκB 
phosphorylation to reduce the level of IκB in HCC. The study further showed that 
ZBP-89 could form a complex with either IκB or pIκB, suggesting a possible 
direct interaction between them. These findings seem to assume that ZBP-89 
 117
promotes IκB degradation via enhancing IκB phosphorylation to activate NF-κB, 
which may lead to the reduction of HDAC3. To verify this assumption, the study 
employed three different inhibitors to block NF-κB activity. CAY10576 and 
MG132 can prevent the degradation of IκB to block the activation of NF-κB 
(Bamborough et al., 2006,Ortiz-Lazareno et al., 2008). SN50 inhibits p50/p65 
nuclear translocation rather than IκB degradation to block the activation of NF-κB 
(Lin et al., 1995,Sun et al., 2012). Unexpectedly, though all these three inhibitors 
can block the activation of NF-κB, ZBP-89-mediated HDAC3 reduction can be 
prevented by only CAY10576 and MG132 but not SN50. Therefore, the decrease 
of IκB or the increase pIκB rather than the elevated activity of NF-κB contributes 
to ZBP-89-mediated HDAC3 reduction in HCC.     
 
To further explore the relevant mechanism of ZBP-89-mediated the reduction of 
HDAC3, the role of Pin1 was studied in this pathway since Pin1 can bind to 
HDAC3 to cause HDAC3 degradation (Rajendran et al., 2011), and Pin1 is 
overexpressed in HCC (Pang et al., 2007,Pang et al., 2006,Chen et al., 2006,Pang 
et al., 2004). The study found that the inhibition of Pin1 increased the level of IκB 
and that Pin1-knocked-out cells Pin1−/− possessed higher levels of HDAC3 and 
pHDAC3 than cells with Pin1 overexpression (Pin1+/+ cells), indicating that Pin1 
may negatively regulate HDAC3 via decreasing the level of IκB in HCC cells. 
The study further demonstrated that downregulation of Pin1 abrogated 
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ZBP-89-mediated HDAC3 decrease. The similar results were also found in Pin1−/− 
and Pin1+/+ cells. Due to the Pin1 deletion, the effect of ZBP-89 on HDAC3 was 
absent in Pin1−/− cells, whereas ZBP-89 significantly decreased HDAC3 in Pin1+/+ 
cells. These findings suggest that the level of ZBP-89-mediated HDAC3 requires 
the presence of Pin1 whose level is negatively associated with IκB. 
 
In conclusion, the study reveals that in HCC, ZBP-89 attenuates HDAC3 protein 
through increasing IκB phosphorylation and/or IκB degradation but such 
attenuation is independent of NF-κB activity and that this process requires the 
presence of Pin1 whose level is negatively associated with IκB.  
ZBP-89-mediated HDAC3 reduction may play a positive role in its ability to 
increase Bak and induce apoptosis of HCC cells, as the inhibition of HDAC3 
leads to the increase of Bak (Mohana et al., 2007), and enhances the efficacy of 













Chapter Four: Conclusions and Future Perspectives  
Chapter Four 




4.1 Summary of results 
1. The expression of Bak was reduced but the levels of DNMT1 and HDAC3 were 
increased in HCC cancer tissues compared to the corresponding non-cancer 
tissues. There was a negative correlation between Bak expression and DNMT1 
levels in HCC.   
2. ZBP-89 downregulated HDAC3 gene expression and suppressed the activities 
of HDACs and DNMTs, which led to maintenance of histone acetylation status 
and inhibited the binding of methyl-CpG-binding protein 2 (MeCP2) to genomic 
DNA and demethylation of CpG islands in the Bak promoter.  
3. ZBP-89 as well as HDAC inhibitor valproic acid (VPA) or/and DNMT inhibitor 
zebularine stimulated Bak expression and induced apoptosis of tumor cells in an 
HCC xenograft mouse model, arresting tumor growth. 
4. Besides reduction of HDAC3, ZBP-89 induced IκB phosphorylation to inhibit 
IκB. Furthermore, Pin1 downregulation partly abrogated ZBP-89-mediated 
HDAC3 decrease. HCC nude mouse model also confirmed that ZBP-89 inhibited 
HDAC3 expression. 
5. ZBP-89-mediated HDAC3 reduction was prevented by CAY10576 and MG132 
but not SN50, indicating that IκB decrease or pIκB increase rather than the 
elevated activity of NF-κB contributed to HDAC3 reduction.  
6. The inhibition of Pin1 increased IκB and HDAC3 level was much higher in 
Pin1−/− cells than in Pin1+/+ cells, suggesting that Pin1 downregulated HDAC3 via 
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decreasing IκB.  
 
4.2 Conclusions 
1. ZBP-89 upregulates the expression of Bak in HCC by targeting multiple 
components of the epigenetic pathway in HCC. Inhibition of HDAC1 and 
DNMT1 contributes to ZBP-89-mediated Bak expression. 
2. ZBP-89 attenuates HDAC3 through increasing pIκB and/or IκB degradation but 
such attenuation is independent of NF-κB activity and this process requires the 
presence of Pin1. The novel pathway identified in HCC may help generate new 
strategy to target HDAC3 and its related molecules. 
 
4.3 Future Perspectives 
Epigenetic therapy against tumors has intensively attracted scientists’ attention. 
Some epigenetic drugs are approved for cancer chemotherapy, and many under 
clinical trials, showing potential effectiveness and safety in patients. As epigenetic 
drugs usually target enzymes, which are commonly used by ordinary biological 
procedures. The mistargeted drugs may cause adverse effects. Therefore, the 
utmost importance issue in application of epigenetic drugs will be the 
understanding of the underlying mechanisms.  
 
Aberrant promoter methylation occurs very early during carcinogenesis and can 
be detected in the normal cells of some patients. DNA methylation status will also 
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be valuable as a prognostic indicator. Drugs targeting DNMTs may normalize and 
open the methylated TSGs in cancer cells. Further understanding of the commonly 
methylated genes in HCC may be very valuable in guiding treatment options 
based on an improved understanding of patient prognosis. Ongoing studies will 
address whether DNA methylation measurement and, importantly, which gene and 
which technique may be useful in predicting an individual patient’s risk for tumor 
development and in developing as targets for anti-tumor therapeutics. Future 
studies about ZBP-89 and HDAC3 and DNMT1 will focus on their biological 
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